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Abstract
Antibiotic resistance is a world-wide occurring problem which threatens hu-
man health. Without development of any new and effective antibiotics, the
rapid growth of antibiotic-resistant bacterial infections could put society in a
situation resembling the pre-antibiotic era when a simple lung infection could
kill a human being. This thesis presents two venues for targeting antibiotic
resistance.
Pathogenic bacteria present in mucus rich environments are able to uti-
lize host-derived sialic acid either as an alternative food source or by incor-
porating sialic acid to their surface glycoconjugates as a way to evade the
host´s immune system. Hence, molecular mimicry enables bacteria to secure
an ecological niche for survival. Transport of scavenged sialic acid into the
cytoplasm of bacteria occurs through specific membrane bound sialic acid
transporters.
The cell wall is an essential protective barrier for bacteria. The membrane
bound enzyme MraY catalyzes the synthesis of lipid I, an intermediate step
in the biosynthesis of peptidoglycan, the cell wall of bacteria.
This thesis presents work aimed to structurally and functionally charac-
terize sialic acid transporters and MraY for future development of antibac-
terial drugs. Starting with a broad approach for expression and purification
of sialic acid transporters resulted in low-resolution diffracting crystals of
the Pasteurella multocida sialic acid TRAP transporter. In addition the X-
ray crystallography structure of the sialic acid transporter SiaT from Pro-
teus mirabilis was determined at 1.95 Å resolution in a substrate-bound
outward-open conformation revealing a new sodium site. Furthermore, SiaT
transporters have been characterized in vivo and the sialic acid specificity has
been characterized for SiaT from Staphylococcus aureus. Structural compari-
son between MraY and the human homologue GPT have highlighted regions
where to modify the natural product inhibitor tunicamycin to selectively
target MraY. Further characterization of tunicamycin analogues identified
potent inhibitors with reduced eukaryotic toxicity.
v

Sammanfattning på svenska
Vi lever i en värld där vi är beroende av antibiotika för att bland annat
kunna genomföra en rad olika medicinska ingrepp. Antibiotika förhindrar
tillväxten av bakteriella infektioner. Tyvärr står världen inför ett stort prob-
lem då användandet av antibiotika missköts vilket leder till att bakterier som
har utvecklat resistens mot antibiotikan har möjlighet att överleva. I denna
avhandling presenteras två möjliga vägar för att utveckla nya antibakteriella
läkemedel.
Patogena bakterier som lever i slemrika miljöer kan ta upp sialinsyra
från sin omgivning och använda det antingen som föda eller för att inkor-
porera sialinsyran på dess lipopolysackarider som finns på bakteriens yta.
Genom att täcka cellytan med sialinsyra undviker bakterien att bli upptäckt
av immunförsvaret. För att kunna utnyttja sialinsyra behöver bakterierna
transportera sialinsyra in i cellen, en process som sker med specifika sialin-
syratransportörer.
En bakteriecell omges av en cellvägg som fungerar som en skyddande
barriär och är nödvändig för bakteriens överlevnad. Cellväggen är uppbyggd
av ett peptidoglykanlager och ett av enzymen som skapar det här lagret är
det membranbundna proteinet MraY.
Följande avhandling presenterar struktur- och funktionsstudier av sialin-
syratransportörer samt MraY som ett steg i att i framtiden kunna utveckla
antibakteriella läkemedel som inhiberar dessa proteiner.
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Chapter 1
Introduction
In our body as well as in any living organism, you can find the most incredi-
ble nanomachines, proteins. Proteins are recognized as important biological
molecules essential to all forms of life. Characterization and structure de-
termination of proteins allow us to understand their role and function in
different processes. A chemical substance with a biological effect, often re-
ferred to as a drug, can be used to treat, prevent and cure diseases. Drugs
are commonly discovered in one out of two ways; knowing the biological ef-
fect before the molecular target is identified or by knowing the molecular
target first. Once a drug target has been identified and characterized, small
compounds are investigated for a desired effect. Elucidating the structure of
a drug target aids the development of new drugs.
Over the years antibiotics have saved millions of lives. However, the ef-
ficacy of antibiotics is reduced by the rapid emergence of resistant bacteria.
Global health is threatened by a combination of overuse, misuse and lack of
new developed antibiotics. Through the work within this thesis two potential
drug targets, for the development of new antibiotics, have been structurally
and functionally investigated.
1.1 Antibiotics and antibiotic resistance
Bacteria, one of the first life forms to appear on Earth, are diverse and their
existence is widespread, from the bottom of the ocean to the inside of our
intestines. Through natural selection bacteria adapt to acquire properties to
survive in specific environments.
The era of antibiotics begun in the 1940s through the introduction of
penicillin, first discovered by Alexander Fleming in 1928. Antibiotics have
been recognized as one of the greatest advances in therapeutic medicine,
saving countless of lives. With the help of antibiotics, a number of advanced
clinical processes such as cancer chemotherapy and organ transplantation
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are now routine procedures [1]. As antibiotics started to emerge, some bac-
teria also started to develop resistance towards these compounds. Antibiotic
resistance is one of the most serious health threats of our time. It is a natu-
rally occurring process, accelerated by the overuse of antibiotics in humans
and animals.
Antibiotics inhibit the growth of microorganisms and can be synthetically
produced as well as produced by both bacteria and fungi. Moreover, antibi-
otics target essential biological processes within bacteria, including cell wall
biosynthesis, DNA replication, transcription and translation [2]. Resistance
towards antibiotics occur when bacteria change their response towards the
antibiotics and the ability of the antibiotics to effectively inhibit bacterial
growth is severely reduced. Mechanisms which compromises the effectiveness
of an antibiotic and therefore make the bacteria resistant, includes decreased
uptake of the drug, efflux pumping of the drug and expression of enzymes
which inactivate antibiotics [3,4]. Less effective antibiotics cause problems in
the treatment of infections such as pneumonia, tuberculosis, blood poison-
ing, gonorrhoea and foodborne diseases. Some bacteria have developed the
ability to resist not only one but several antibiotic drugs simultaneously, giv-
ing rise to multidrug resistant bacteria [5]. Without the development of new
antibiotics, the global threat of antibiotic resistance will not be constrained.
1.2 Membrane proteins
Proteins are versatile and crucial macromolecules in living systems. They
are built up by a linear polymer of amino acids, which folds into a spe-
cific three-dimensional structure determined by the amino acid sequence.
The twenty amino acids, which act as building blocks of the polypeptide, all
have different properties. They vary in size, shape, charge, hydrogen bond-
ing capacity, hydrophobic character and chemical reactivity. By elucidating
the structure of these important macromolecules, we will have access to a
detailed map, which aids in the understanding of the function of the pro-
tein. Specific proteins, called membrane proteins, are embedded in a lipid
bilayer. Membrane proteins are involved in the transport of molecules in and
out of the cell, propagation of electrical impulses, control of membrane lipid
composition, receiving chemical signals, regulation of intracellular vesicular
transport, energy-converting processes etc [6]. Membrane proteins span the
lipid bilayer and is therefore exposed to a highly amphiphilic environment.
Lipid head groups occupy a layer in each end of the lipid bilayer, leaving a
hydrophobic region in-between.
2
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The architecture of the transmembrane proteins is mostly either α-helical
bundles or β-barrels. The helix-bundle proteins are medically important and
functionally diverse. A majority of all drug targets are membrane proteins,
and these are therefore an important class of proteins for the pharmaceuti-
cal industry [7]. Hydrophobic amino acids are the dominant type of amino
acids in the lipid-exposed regions of transmembrane helices. Amino acids
important for function of the protein are predominantly facing the interior
of the protein, embedded between hydrophobic residues. There is a strong
tendency for positively charged amino acids like lysine and arginine to face
the cytoplasm (inside of the cell) in contrast to the periplasm (outside of
the cell); this in known as the “positive-inside rule” and it can be used for
predicting the topology of membrane proteins [8, 9]. About 20-30% of all
genes in both prokaryotes and eukaryotes encode membrane proteins [10].
1.3 Secondary transporters
Movement of small molecules across a lipid bilayer is facilitated by trans-
porters. Secondary transporters can be classified as either symporters or
antiporters. Symporters transport the ion and substrate in the same direc-
tion across a lipid bilayer whereas an antiporter transports the substrate and
ion in opposite directions. Secondary transporters are driven by transmem-
brane electrochemical gradients generated by primary active pumps. The
separation of charged molecules establish a membrane potential, which is lo-
cated near the membrane. Secondary transporters couple the uphill transport
of a substrate with the downhill transport of another (mostly ions) across
the lipid bilayer. The direction of substrate transport is determined by the
combined electrochemical potentials of the substrate and the driving solute.
Secondary transporters are also expected to be fully reversible [11]. The sto-
ichiometry between substrate and driving ion may vary, but it is important
to note that the substrate and driving ion are always co-transported.
3
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1.3.1 The alternating access mechanism
Alternating access to the substrate binding site from either side of the mem-
brane is the basis of the alternating access mechanism. It is a widely used
mechanism to describe the alternating conformation of the substrate binding
site in the process of delivering the substrate from one side of the membrane
to the other [12]. An allosteric coupling of the extracellular and intracellular
gates of the transporter creates an alternating access of the two sides. The
transport of substrate and ions proceeds in a number of intermediate steps
that are each separated by energy barriers (Figure 1.1). Without interme-
diate steps which occlude the substrate from either side of the membrane,
a transporter which moves its substrate against a concentration gradient
become less efficient due to continuous association and dissociation of the
substrate to the binding site [13]. The alternating access mechanism can be
divided into three major mechanisms: the rocker switch, the rocking bundle
(gated pore) and the elevator model [11].
Figure 1.1: The alternating access mechanism of a symporter. A simple
mechanism representation of the alternating access of the substrate binding site,
through a number of interconversion steps. For a symporter both the substrate and
the co-transported ion(s) needs to bind before the protein changes conformation
and exposes the substrate binding site to the other side of the membrane. Figure
inspired from [13].
4
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The coupled movement between an outside and inside gate around a
centrally located substrate binding site is catalyzed by substrate binding in
the rocking-bundle alternating access mechanism [13]. In 2005 the crystal
structure of the amino acid sodium symporter LeuT from Aquifex aeoli-
cus (LeuTAA) of the neurotransmitter sodium symporter (NSS) family was
determined at 1.65 Å resolution using X-ray crystallography [14]. This trans-
porter consists of twelve transmembrane helices, where the first ten build up
the structural core of the protein in a fold subsequently named the LeuT-fold
(Figure 1.2). The transmembrane helices TM1-TM5 and TM6-TM10 are re-
lated to each other by a pseudo-two-fold axis located in the membrane plane.
TM1 and TM6 are oriented antiparallel to each other and are non-continuous
helices, the breaks in these helices are located approximately halfway across
the membrane bilayer. This conserved transporter architecture is character-
ized by three structural elements. The helix bundle (core domain) which
consists of the first two helices of each repeat (TM1-TM2 and TM6-TM7),
the hash domain (scaffold domain) consisting of the third and fourth helix of
each repeat (TM3-TM4 and TM8-TM9) and the two peripheral arms which
correspond to the fifth helix of each repeat (TM5 and TM10) [11, 15]. The
two discontinues helices (TM1 and TM6) from the core domain make up a
large fraction of the substrate and sodium binding sites.
Figure 1.2: The LeuT-topology with two inverted repeats of five trans-
membrane helices. The three structural elements are indicated with different
colors: the helix bundle (core domain) which consists of TM1-TM2 and TM6-TM7
(beige), the hash domain (scaffold domain) which consists of TM3-TM4 and TM8-
TM9 (purple) and the two peripheral arms which correspond to TM5 and TM10
(green). The position of the substrate- and sodium binding sites are indicated with
diamond (brown) and spheres (blue), respectively. Figure inspired from [14].
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The rearrangement upon gating varies between rocking-bundle trans-
porters with the same fold [11]. Detailed descriptions of the alternating access
mechanism have been obtained from crystal structures of BetP, LeuT and
Mhp1 [16–18] in different conformations.
1.3.2 Sodium binding sites
The driving force for sodium-coupled symport is the sodium ion electrochem-
ical gradient, nevertheless there is a variation in the number of sodium bind-
ing sites and the stoichiometry between sodium: substrate which is trans-
ported across the lipid bilayer among proteins with the LeuT-fold.
In the first structure of LeuTAA [14], two sodium binding sites were
identified. The two sodium binding sites Na1 and Na2, were located halfway
across the membrane bilayer, at the unwound regions of TM1 and TM6
within 6 Å away from the substrate binding site. The Na1 sodium ion is
octahedrally coordinated by amino acid residues from TM1, TM6 and TM7
as well as via the carboxyl oxygen of the substrate leucine. Na2 is coordi-
nated by a trigonal bi-pyramidal configuration through amino acid residues
from TM1 and TM8. The Na2 position between TM1 and TM8 is ∼7 Å away
from the Na1 site and 5.9 Å away from the substrate binding site. Additional
members of the NSS family which have also been structurally determined
and which possess two sodium binding sites (Na1 and Na2) are the mulithy-
drophobic L-amino acid transporter MhsT from Bacillus halodurans [19] and
the dopamine transporter from Drosophila melanogaster dDAT [20].
The bacterial sodium galactose transporter from Vibrio parahaemolyticus
(vSGLT) is the first structurally determined representative of the sodium so-
lute symporter (SSS) family and this protein possesses the conserved Na2
site [21]. vSGLT has been structurally determined in inward-facing confor-
mations in an apo [22] and substrate-bound [21] form. The benzyl-hydantoin
transporter Mhp1 belongs to the nucleobase-cation-symporter (NCS1) fam-
ily, and possesses one sodium binding site (Na2) [23].
In the betaine transporter BetP, which belongs to the betaine/choline/
carnitine (BCC) family, the stoichiometry between transported substrate and
sodium has been determined to be 1:2 [15, 24]. The position of the second
sodium binding site in BetP (Na1´) was proposed based on structural ho-
mology between repeats [25].
The Na2 site is a conserved (non-optional) sodium binding site among
transporters with the LeuT-fold [15]. However, the presence of the additional
non-conserved Na1 and Na1´ sites might be related to the specificity of the
co-transported substrate.
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1.4 Sialic acid transport
1.4.1 Sialic acid
Sialic acid, also called neuraminic acid, is a large family of nine-carbon
sugar acids with among 50 structurally distinct compounds identified [26].
The most abundant and well-studied sialic acid is the 2-keto-3-deoxy-5-
acetamido-D-glycero-D-galacto-nonulosonic acid (N -acetylneuraminic acid
or Neu5Ac) (Figure 1.3) [26], an amino sugar derivative of N -acetylmannos-
amine and pyruvic acid. The neuraminic acid ring of Neu5Ac has an ac-
etamido group at the C5 position and a glycerol tail composed of carbons
7-9, at the C6 position. The majority of sialic acid derivatives have substitu-
tions at the C5 position and at the hydroxyl groups of the C4, C7, C8 and
C9 positions [27].
Figure 1.3: Sialic acid The structure of the three sialic acid derivatives Neu5Ac,
Neu5Gc and KDN. In addition, the α- and β-anomer of Neu5Ac are displayed,
carbon atoms are numbered from 1 to 11 and differences are higlighted with a
grey circle.
7
Chapter 1. Introduction
The second most common sialic acid of most vertebrates, N -glycolyl-
neuraminic acid (Neu5Gc), differs from Neu5Ac by the addition of a hy-
droxyl group at the C11 position (Figure 1.3). Interestingly Neu5Gc has
never been detected in bacteria [26]. In humans, Neu5Gc is endogenously
absent, since the gene encoding the hydroxylase which adds the N -glycolyl
group in Neu5Gc is inactive [26, 28]. Deaminated neuraminic acid (KDN)
(Figure 1.3) occurs widely among vertebrates and bacteria. Its abundant
occurrence in animals is limited to lower vertebrates [29].
The carboxylate group (pKa of 2.6) of sialic acid gives it its net nega-
tive charge at physiological pH. Sialic acid can exist in both the α- and β-
conformation. In general, sialic acid is released as the α-conformation from
the glycoconjugates and subsequently converted into its β-conformation be-
fore transported into the cytoplasm [27,30]. By mutarotation both forms can
be interconverted as the ring opens to a straight-chain conformation followed
by ring closure [26].
1.4.2 Distribution and significance of sialic acid
Sialic acid is positioned at the terminal end of glycoconjugates in both eu-
karyotes and prokaryotes. This position allows them to participate in in-
teractions with the external environment, such as cell-cell communication
and self-recognition. In humans the highest concentration of sialic acid is
found in the brain and utilized in the central nervous system [31]. Mucus-
rich environments like the respiratory and gastrointestinal tracts in humans
are also rich in sialic acid with over 65% of glycans containing sialic acid
residues [32,33].
Many pathogenic bacteria have evolved the ability to use sialic acid as
a shield of protection, by decorating their cell-surface. It gives them a pro-
tection against the host´s immune response [34]. The decoration of bacterial
surfaces have been observed for lipopolysaccharides (LPS) in Gram negative
bacteria; the flagellum and the capsular polysaccharides [31].
Sialic acid can also be used as a source of nutrition for the bacteria.
Catabolism of Neu5Ac is associated with commensal and pathogenic bacteria
[35, 36]. In bacteria, Neu5Ac is catabolized by five enzymes: N -acetyl-
neuraminic acid lyase (NanA), N -acetylmannosamine kinase (NanK),
N -acetylmannosamine 6-phosphate epimerase (NanE),N -acetylglucosamine-
6-phosphate deacetylase (NagA), glucosamine-6-phosphate deaminase
(NagB) yielding fructose-6-phosphate and ammonia [31]. The enzymes in-
volved in degradation of Neu5Ac in Escherichia coli are all located within
the nan operon (nanATEK-yhcH) regulated by the nanR repressor, located
upstream of nanA [31]. Furthermore, the nanCMS operon is also regulated
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by the NanR repressor protein. The genes encoded by the nanCMS operon
includes the outer membrane porin (NanC), sialate mutarotase (NanM) and
sialate O-acetyl esterase (NanS) [31].
Bacteria are able to scavenge free sialic acid from the environment, in
addition bacteria synthesize sialidases, enzymes which cleaves terminal sialic
acid from the eukaryotic host´s glycoconjugates [31,37]. The acquired sialic
acid is further transported into the cytoplasm of the bacterial cell by specific
sialic acid transporters [30]. In eukaryotes, the synthesis of Neu5Ac takes
place in the cytoplasm. Subsequently, Neu5Ac is activated in the nucleus
to CMP-Neu5Ac and transported into the Golgi apparatus by a specific
CMP-Neu5Ac transporter [38] where it is recognized by sialyltransferases
and attached to glycoproteins or glycolipids.
1.4.3 Sialic acid import across the bacterial cytoplasmic
membrane
Bacteria transport sialic acid across their cytoplasmic membrane using spe-
cific sialic acid transporters. There are four different classes of transporters
known to transport sialic acid (Figure 1.4). The type of transporter can
vary between different bacterial species. The four different classes of sialic
acid transporters include the ATP-binding cassette (ABC), tripartite ATP-
independent periplasmic (TRAP), major facilitator superfamily (MFS) and
sodium solute symporter (SSS) family [39]. It is not completely understood
why some bacterial pathogens have more than one type of sialic acid trans-
porter; possibly it can be related to the large variation of sialic acids [39].
Bacterial sialic acid transporters have low homology with the human sialic
acid transporter and is therefore a valid antibacterial target.
ABC transporters
One of the largest families of transporters is the ABC superfamily [40]. The
ABC-transporter family utilizes the energy generated from ATP-hydrolysis
in the transport of a variety of substrates across the extracellular and in-
tracellular membranes [41, 42]. In 2005, the first sialic acid transporter of
the ABC-type was identified and characterized in Haemophilus ducreyi [43].
The sialic acid ABC transporter consists of four subunits: the periplasmic
substrate binding subunit SatA, the integral membrane subunits SatB and
SatC and the nucleotide binding domain SatD located in the cytoplasm.
Furthermore, in H. ducreyi the SatC subunit contains both an N-terminal
transmembrane domain and a C-terminal nucleotide binding domain [43].
9
Chapter 1. Introduction
Figure 1.4: Overview of the different types of sialic acid transporters
located in the cytoplasmic membrane of bacteria. ABC-transporter; gen-
erally composed of two transmembrane domains and two nucleotide binding do-
mains which hydrolyze ATP. The Sat subunits (SatA, SatB, SatC and SatD) are
labeled. TRAP-transporters are built up by three domains, the substrate bind-
ing domain (SiaP) and a large and small membrane spanning domain (SiaQ and
SiaM). SSS-transporters (SiaT) and MFS-transporters (NanT) both consist of a
single transmembrane spanning domain. Sialic acid is illustrated as red circles.
TRAP transporters
TRAP transporters are present in both bacteria and archaea, but not in
eukaryotes [44]. The first TRAP transporter was identified in 1997 [45] and
it uses an electrochemical gradient to facilitate the transport of solute over
the membrane. Whether the TRAP transporter is dependent on protons or
sodium ions is unclear. The first sialic acid TRAP transporter was charac-
terized from Haemophilus influenzae [46, 47]. The TRAP-transporter is the
predominant type in Pasteurellaceae and Vibrionaceae [48]. The sialic acid
TRAP transporter is built up by three subunits. The periplasmic substrate
binding subunit SiaP, which delivers sialic acid to the membrane protein
subunits, SiaQ and SiaM. For some bacterial organisms these two subunits
are fused together forming a SiaQM integral membrane subunit.
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MFS transporters
The first sialic acid transporter to be discovered was NanT from E. coli [49].
This secondary transporter belongs to the major facilitator family (MFS)
which uses the proton electrochemical gradient in the co-transport of sialic
acid [26,50,51]. Interestingly, the NanT transporter is predicted to comprise
of 14 transmembrane helices, this is two more than the usual 12 transmem-
brane helices of MFS transporters [50, 52]. The NanT transporter is mainly
found in Enterobacteriaceae [48].
SSS transporters
In 2010 the sialic acid transporter SiaT from Salmonella enterica servoar
Typhimurium was identified as a sialic acid transporter of the SSS family
[51]. The gene encoding SiaT is widespread in both Gram positive and Gram
negative bacteria [51] including the human bacterial pathogens Staphylocccus
aureus [53], Phobacterium profundum [54], Clostridium perfringens [55] and
Clostridium difficile [56]. Furthermore, the SiaT transporter is predominant
among Firmicutes [48]. The driving force for the SSS-transporters, which
co-transports a number of different substrates with sodium ions [57], is a
combination of the negative membrane potential and the intracellular low
concentration of sodium ions [21,58].
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1.5 Bacterial cell wall biosynthesis
1.5.1 The bacterial cell membranes
Targeting proteins involved in the bacterial cell wall biosynthesis is a valid
approach to develop novel antibiotics, since mammalian cells lack a cell wall.
A prokaryotic cell protects its content with a cytoplasmic membrane.
The cytoplasmic membrane consists of a phospholipid bilayer with embed-
ded proteins which are involved in numerous of different processes within the
cell, including the control of passage of molecules in and out of the cell. Most
prokaryotic cells also surround themselves with a cell wall, a peptidoglycan
layer, with the function to protect the cell from mechanical injury and pre-
vent it from bursting. The two characteristically different prokaryotic cell
types are the Gram positive and Gram negative (Figure 1.5).
A Gram negative bacteria is surrounded by two membrane layers, an
outer membrane and an inner membrane, as opposed to the Gram posi-
tive bacteria which only possess the inner cytoplasmic membrane. The outer
membrane of Gram negative bacteria is rich in lipopolysaccharides (LPS).
Furthermore, the cell wall is built up by a peptidoglycan layer, which is
thicker in Gram positive bacteria than in Gram negative bacteria [59]. Due
to its extra outer membrane layer, the Gram negative bacteria is much more
effective in blocking antibiotics from entering the cell [60, 61]. Proteins in-
volved in bacterial cell wall biosynthesis are highly conserved and often es-
sential [62], hence they are suitable potential antibiotic targets.
Figure 1.5: Illustration of the Gram positive and the Gram negative cell
membranes. Indicated are the inner cytoplasmic membrane (IM) and the outer
membrane (OM). The peptidoglycan layer is illustrated as a cross-linked network
(black) and is significantly thicker in Gram positive bacteria compared to Gram
negative bacteria. Shown are membrane proteins (orange), porin (green), periph-
eral membrane proteins (brown), lipopolysaccharide (green), lipoprotein (blue)
and teichoic acids (purple). Figure inspired from [61].
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1.5.2 Peptidoglycan biosynthesis
The cytoplasmic membrane of bacteria is surrounded by a peptidoglycan
layer, also called murein. It is essentially a specific macromolecule which
acts as a protective barrier for the cell [63]. The peptidoglycan layer gives the
bacterial cell its specific shape and allows it to withstand osmotic pressure;
it can also be used as a scaffold for anchoring other proteins [63,64].
Figure 1.6: Illustration of a cross-linked peptidoglycan layer.
Peptidoglycan are linear glycan strands cross-linked by short peptides
(Figure 1.6) [63, 65]. Alternating N -acetylglucosamine (GlcNAc) and N -
acetylmuramic acid (MurNAc) residues are linked together by β-1,4 gly-
cosidic bonds in each glycan strand. A peptide chain is substituting the
D-lactoyl group of each MurNAc residue in peptidoglycan. In the mature
macromolecule the last D-Ala residue of each peptide chain is lost. Cross-
linking between glycan strands often occurs between the carboxyl group of
D-Ala at position 4 and the amino group of the diamino acid at position 3
by either direct cross-linking or by a short peptide bridge [63]. Variations of
the glycan strands, the peptide strand and the position or composition of
the interpeptide bridge occur in different bacterial species [63].
The peptidoglycan layer is assembled in three phases. In the first phase
which takes place in the cytoplasm of the bacterial cell, several soluble en-
zymes (MurA, MurB, MurC, MurD, MurE and MurF) are invovled in the
synthesis of UDP-N -acetylmuramyl-pentapeptide (UDP-MurNAc-penta-
peptide). In the second phase, the two membrane bound enzymes MraY
and MurG are involved in reactions occurring on the cytoplasmic surface
of the inner membrane of the bacterial cell. MraY catalyzes the transfer
of the phospho-MurNAc-pentapeptide motif of UDP-MurNAc-pentapeptide
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to the lipid carrier undecaprenyl phosphate, generating lipid I in the first
membrane-bound step. Secondly, MurG catalyzes the transfer of the GlcNAc
motif of UDP-GlcNAc to the C4 hydroxyl MurNAc in lipid I to produce the
lipid-linked β–1,4 disaccharide known as lipid II. Lastly in the third phase,
lipid II is translocated to the exterior surface of the cell by an unknown
mechanism [66–69]. The membrane protein MraY will be further described
in chapter 1.5.5.
1.5.3 The PNPT superfamily
The polyprenyl-phosphate N -acetylhexosamine 1-phosphate-transferase
(PNPT) superfamily includes prokaryotic enzymes responsible for bacterial
cell wall biosynthesis and eukaryotic enzymes involved in N -linked glyco-
sylation. This family of enzymes catalyzes the transfer of a phospho-N -
acetylhexosamine from a cytoplasmic UDP-N -acetylhexosamine sugar nu-
cleotide donor substrate to a membrane-bound polyprenyl phosphate accep-
tor substrate [70]. MraY, WecA, WbcO, WbpL and RgpG are all enzymes
of the PNPT superfamily; they differ in their specificity for the UDP-sugar
donor substrate but use the same lipid substrate, undecaprenyl-phosphate
(C55-P) [71]. The eukaryotic member of the PNPT family, GPT (UDP-
N -acetyl-glucosamine: dolichyl phosphate N -acetylglucosamine-1-phosphate
transferase or GlcNAc-1-P-transferase), is essential for N -linked glycosyla-
tion and located within the endoplasmic reticulum (ER) membrane. GPT
uses UDP-GlcNAc and dolichol phosphate as the soluble and lipid substrate,
respectively [72].
1.5.4 Natural product inhibitors
Identifying small molecules with antibacterial activity, especially for multidrug-
resistant Gram negative pathogens, has proven to be challenging. The abil-
ity of an antibiotic compound to penetrate the bacterial cell wall is lim-
ited by the protective barriers, including cell membranes, complex carbohy-
drate networks and efflux pumps, in both Gram negative and Gram positive
bacteria [73]. Pharmaceutical companies often use high-throughput screen-
ing (HTS) as a conventional drug discovery approach. However, this ap-
proach has not been as successful for the identification of novel antibacterial
drugs [74]. An alternative approach is to investigate natural product in-
hibitors as scaffolds for the development of novel antibiotic drugs.
MraY has lately been suggested as a promising antibiotic target. An an-
tibiotic aimed to inhibit MraY has to be able to cross the protective barriers
and to reach the active site of MraY, which is located on the cytoplasmic side
14
1.5. Bacterial cell wall biosynthesis
of the membrane. It is also necessary to avoid toxicity issues by selectively
target MraY over any other translocases. Furthermore, the antibiotic needs
to possess good inhibitory activity against MraY.
Peptide inhibitors, nucleoside- and lipopeptide antibiotics are all natural
product inhibitors that block the synthesis of lipid I, the product of MraY
[75]. The lipopeptide amphomycin is a non-competitive inhibitor of MraY
which forms a complex with the lipid substrate C55-P in the presence of Ca2+
[76]. Protein E is a peptide produced by the bacteriophage ΦX-174 which
inhibits MraY by binding at an allosteric site [75]. The group of nucleoside
antibiotics can be divided into different sub-groups based on their chemical
differences and/or mode of action against MraY, for example tunicamycins,
ribosamino-uridines, uridylpeptides and capuramycins [75].
Figure 1.7: The natural product inhibitors tunicamycin and mu-
raymycin D2 (MD2). The fatty acyl chain of tunicamycin can vary in length
and branching.
Tunicamycin is a uridine-derived nucleoside antibiotic that consists of a
uracil motif, a tunicamine sugar, an N -acetylglucosamine sugar (GlcNAc)
and a fatty acyl chain (Figure 1.7). It is considered as a competitive in-
hibitor relative to MurNAc, the sugar nucleotide donor, and not competitive
towards the undecaprenyl-phosphate substrate [77]. Tunicamycin was first
discovered in 1971, as it was isolated from the fermentation broth of Strep-
tomyces lysosuperficus due to its antiviral properties [78]. The synthesis of
lipid I is blocked by tunicamycin in Gram positive bacteria [78,79] in contrast
to Gram negative bacteria [80] where tunicamycin is unable to penetrate
the outer cell membrane. It is also toxic towards eukaryotes by inhibiting
GPT [75,78]. Tunicamycin is not a suitable antibiotic drug, although reduced
eukaryotic toxicity has been observed for modified tunicamycins [81,82].
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Muraymycins are uridine-derived nucleoside-peptide antibiotics, first iso-
lated from a broth of a Streptomyces sp. in 2002 [83]. The structure of mu-
raymycin consist of a glycyl-uridine motif connected via an aminopropyl
linker to a urea peptide moiety, and at the 5´-position the uridine is gly-
cosylated with an aminoribose unit (Figure 1.7). Some derivatives of mu-
raymycin have a lipophilic side chain attached at the hydroxyleucine residue
of the peptide moiety [84]. In contrast to tunicamycin, most muraymycin
analogues are not cytotoxic. Muraymycin D2 (MD2) has been reported to
inhibit MraY, although it does not possess favorable cell permeability char-
acteristics, hence does not show any antibacterial activity [85].
1.5.5 MraY
MraY (UDP-N -acetylmuramyl-pentapeptide: undecaprenyl phosphate
N -acetylmuramyl-pentapeptide-1-phosphate transferase or MurNAc-1-P-
transferase) is a membrane bound enzyme involved in the peptidoglycan
biosynthesis of bacteria. It catalyzes the synthesis of C55-PP-MurNAc-
pentapeptide (lipid I) from the lipid substrate undecaprenyl-phosphate (C55-
P) and the soluble substrate UDP-MurNAc-pentapeptide (Figure 1.8). The
first discovery of MraY was made in 1965 in the bacteria S. aureus and
Micrococcus luteus [86, 87], and the complete amino acid sequence along
with the topology have been reported for MraY from both Gram positive
and Gram negative bacteria [88,89].
Over the years, MraY from Gram positive and Gram negative bacteria
have been expressed (recombinantly in E. coli and cell free expression) and
purified [90–94]. Membrane proteins with both the N- and C-termini located
on the periplasmic side are known to be difficult to overexpress, most likely
related to the problems with membrane insertion and folding [95]. Cell-free
expression of Gram negative MraY demonstrated the importance of incor-
porating negatively charged lipids for obtaining a stable and functional en-
zyme [62,91].
Initial biochemical studies to measure MraY enzyme activity was per-
formed with radiochemical assays. Radiolabeled soluble substrate was in-
cubated with lipid substrate and enzyme, followed by extraction of the ra-
diolabeled lipid I product [96]. The modified substrate UDP-MurNAc-L-
Ala-γ-D-Glu-m-DAP(ξ-dansyl)-D-Ala-D-Ala, which contains the dansyl flu-
orophore, can be used as a substrate for MraY and the dansylated lipid I
product exhibit enhanced fluorescence [97]. Subsequently a continuous flu-
orescence assay was developed [77, 80] and extended to an HTS assay [98].
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Figure 1.8: The reaction of MraY. The synthesis of lipid I occurs on the
cytoplasmic side of the inner membrane in bacteria. The lipid substrate C55P re-
acts with the soluble substrate UDP-MurNAc-pentapeptide (UDP-MurNAc-pp)
in a Mg2+ dependent reaction catalyzed by MraY, yielding C55PP-MurNAc-
pentapeptide (C55PP-MurNAc-pp, lipid I) and UMP.
The thin layer chromatography (TLC) translocase assay has been used ex-
tensively [90, 91, 93]. Another valuable assay is the fluorescence resonance
energy transfer (FRET) assay developed in 2012 [99].
The MraY enzyme activity is dependent on the divalent cation magne-
sium (Mg2+) [90]. Amino acids involved in the coordination of the Mg2+ ion
were predicted based on mutational studies [100], sequence similarity of the
Mg2+-binding motif (DDXXD/N) of prenyl transferases [101] along with the
apo structure of A. aeolicus MraY (AaMraY) [93] (Table 1.1).
Enzyme inhibition has previously been demonstrated to be competitive
with Mg2+ for ester-linked 5´-uridinyl dipeptides, where the inhibition of
solubilized E. coli MraY (EcMraY) was decreased with increased concen-
trations of Mg2+ [102]. It was proposed that the primary amino terminus
of the most potent inhibitor interacts with amino acids important for Mg2+
binding in MraY.
The binding affinity between MraY and the natural product inhibitor
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Table 1.1: Amino acids proposed to be involved in Mg2+ coordination.
Amino acids in bold indicate which MraY enzyme that was used as model in the
assignment from the mutational studies (A), Mg2+-binding motif (DDXXD/N) of
prenyl transferases (B) and the structure of AaMraY (C). Amino acids are given
as a reference for Clostridium bolteae MraY (CbMraY).
A B A C
CbMraY [94] His44 Asp93 Asp94 Asp175 Asp178 Asp231
AaMraY [93] His65 Asp117 Asp118 Asp193 Asp196 Asp265
BsMraY [100] His45 Asp98 Asp99 Asp174 Asp177 Asp231
EcMraY [101] His65 Asp115 Asp116 Asp195 Asp198 Asp267
tunicamycin has been determined for Bacillus subtilis MraY (BsMraY) (Kd
= 93 ± 16 µM) using biolayer interferometry (BLI) in the presence of 10
mM MgCl2 [103] and for AaMraY (Kd = 37 ± 1 nM) using isothermal titra-
tion calorimetry (ITC) in the absence of MgCl2 [82]. Interestingly, the bind-
ing affinity constant is significantly different between the two methods and
could be an effect of interfering Mg2+ [82]. For the purpose of determining
the binding affinity between potential inhibitors/modified compounds and
MraY, there is a need for a reliable assay which consumes small amounts of
protein since the yield of purified MraY is often not very high.
Mechanism of MraY
Until 2016, there was a debate regarding the mechanism of MraY. Bouhss
and co-workers concluded that MraY acts via a single displacement mech-
anism (one-step mechanism) where the UDP-MurNAc pentapeptide donor
substrate and the lipid acceptor substrate simultaneously bind to the ac-
tive site of MraY. Furthermore, they propose that a conserved aspartic acid
(Asp98 in BsMraY) is involved in the deprotonation of the lipid substrate al-
lowing for a nucleophilic attack of the pyrophosphate group of UDP-MurNAc
pentapeptide [104]. Docking studies of the substrate analog UDP-GlcNAc
into the active site of CbMraY [94] further strengthens this theory.
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1.6 Scope of this thesis
This thesis presents the work aimed to provide structural and functional
insights into sialic acid transporters which transport sialic acid across the
cytoplasmic membrane of bacteria. In addition, this thesis presents struc-
tural interpretations and binding studies of the enzyme MraY involved in
the synthesis of the bacterial peptidoglycan layer. Both proteins are crucial
to pathogenic bacteria and as such promising candidates for the future de-
velopment of antibacterial drugs.
Chapter 2 gives a brief introduction to some of the methods involved in
protein production, purification and structural determination using X-ray
crystallography and a few biophysical methods used for characterizing these
proteins and the interaction between protein and small-molecule compounds.
Chapter 3 presents results from Paper I – Paper IV, which covers the
sialic acid transporters.
Chapter 4 presents the results obtained in Paper V and Paper VI, which
covers the enzyme MraY.
Chapter 5 summarizes the results and presents a future perspective.
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Chapter 2
Methodology
In theory, the process from target identification to pure protein is straight-
forward (Figure 2.1). In reality there are a number of steps, which needs to
be carefully studied and optimized, especially for membrane proteins.
Figure 2.1: The process from identified gene to pure protein, characterization
and structure determination includes many trial and error experiments.
2.1 The bacterial expression system
Protein structure determination requires high amounts of pure and stable
protein. It is advantageous to use E. coli as the host for recombinant expres-
sion of prokaryotic proteins since it is closely related to the natural source.
Furthermore, recombinant expression in E. coli allows for transformation of
exogenous DNA, it has a short generation time and is relatively inexpensive.
There are also several different modified E. coli strains available, suitable
for different expression systems [105,106].
A common approach for producing recombinantly expressed proteins in
E. coli is to use the T7 system. The T7 expression host DE3 contains a
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chromosomal copy of the phage T7 RNA polymerase gene. Protein expression
in the E. coli strain BL21(DE3), developed for the overexpression of soluble
proteins [107], is driven by the bacteriophage T7 RNA polymerase. T7 RNA
polymerase is responsible for a much faster transcription rate compared to
the E. coli RNA polymerase [108]. More transcribed mRNA will generate
more translated protein, although if the rate is too fast, the protein is not
always correctly folded [105].
Furthermore, the T7 RNA polymerase is under the control of the lacUV5
promoter which can be regulated by the lac repressor and induced with
IPTG. In the T7 system, an expression vector containing the gene of interest
is cloned downstream of the T7 promoter and subsequently transformed
into the E. coli expression host. Upon induction, T7 RNA polymerase is
expressed and available for transcription of the target gene. Overexpression
of membrane protein is often toxic for the host, and a promoter that is not
tightly regulated (e.g the lac promoter) often results in leaky expression. The
E. coli Lemo21(DE3) strain has the ability to control the expression rate by
using the natural inhibitor T7 lysozyme [105]. In E. coli Lemo21(DE3), the
gene encoding T7 lysozyme is on a plasmid which is under the control of a
L-rhamnose promoter (rhaP(BAD)), which is well titrable [109,110].
2.2 Construct design
The amino acid sequence of a protein is encoded within a specific DNA
sequence, a gene. As a first step, it is common to modify the regions flanking
the gene of interest, e.g. include affinity tags, fusion proteins and protease
cleavage sites which will facilitate protein expression and purification among
other things.
One of the most widely used vector systems for recombinant protein ex-
pression in E. coli is the pET expression system [111]. The bacterial expres-
sion vector pET26b(+) has an N-terminal pelB signal sequence which directs
the membrane protein to the membrane, subsequently the leader signal is
removed by a signal peptidase [112].
The commercially available low-copy pWarf-vectors (Figure 2.2) [113,114]
carries a C-terminal human rhinovirus 3C protease (HRV3C) cleavage site, a
green fluorescent protein (GFP)-tag and an 8x histidine-tag. The pWarf(+)
vector also carries a Glycophorin A (GpA) fusion (a single transmembrane
spanning helix) which redirect the GFP into the cytoplasm if the C-terminal
of the target protein is located on the periplasmic side. The soluble GFP
protein is relatively small in size (molecular weight of 27 kDa) and func-
tional as a monomer. Furthermore, GFP emits green light once the internal
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fluorophore Ser-Tyr-Gly is excited with long wave UV-light [115]. To be able
to take advantage of the GFP-tag for detection, it is important to know the
location of the C-terminal of the target protein, since GFP is only functional
in the cytoplasm.
Figure 2.2: Schematics of protein constructs in the pWarf-vectors. The
difference between pWarf(-) and pWarf (+) is the additional Glycophorin A (GpA)
single transmembrane helix motif.
The levels of overexpressed membrane protein in whole cells can be mon-
itored by the levels of expressed GFP, which is fused to the C-terminal of the
membrane protein [113, 116, 117]. If the protein is incorrectly folded, it will
not fluoresce. An additional quality control is to detect the fusion protein on
an SDS-polyacrylamide gel by fluorescence (In-Gel Fluorescence) [117]. It is
also possible to take advantage of the GFP-fusion protein during detergent
screening, in the fluorescent size exclusion chromatography (FSEC) method.
Incorporating an affinity-tag, e.g. a polyhistidine-tag, can be used in
immobilized metal-affinity chromatography (IMAC). This method is based
on the interaction between a transition metal ion immobilized on a matrix
and specific amino acid chains in the protein [118]. It is also possible to
label a polyhistidine-tag with a fluorescent probe and use it in microscale
thermophoresis (MST) experiments or with FSEC [92] (discussed in chapter
4.2.3).
2.3 Purification of membrane proteins
A functional stable and homogeneous membrane protein sample is a good
starting point for crystallization and characterization experiments. Purifi-
cation of overexpressed membrane proteins starts with breaking the cells
and collecting the membrane fraction from which the proteins are extracted.
Subsequently the protein is purified often using an affinity step followed by
size-exclusion chromatography (SEC), as a polishing step.
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2.3.1 Solubilization of membrane proteins
Membrane proteins are embedded in a lipid bilayer and needs to be sol-
ubilized into an aqueous environment where the protein is stable. Due to
the intrinsic hydrophobicity of membrane proteins, they are prone to fold
improperly and aggregate in solution. This is one of the major bottlenecks
in membrane protein research. Solubilization of membrane proteins from
their natural lipid bilayer can be done using detergent molecules. Detergent
molecules are amphipathic molecules, by definition the detergents have a
polar and non-polar region. Above a certain critical micelle concentration
(CMC), they spontaneously form micelles (Figure 2.3). Detergents vary in
charge and size, both within the head group and tail. The average num-
ber of detergent molecules per micelle is denoted as the aggregation number
(NA). Detergents with a longer tail are typically more hydrophobic, hence
are less soluble, which as a consequence results in a lower CMC. Harsh
detergents are often small with a polar head group [119]. Most success-
ful detergents for α-helical membrane protein crystallization have been the
alkyl-maltopyranoside and alkyl-glucopyranoside detergents [120]. A deter-
gent with a short hydrophobic tail has a smaller micelle, which can lead to
denaturation of the protein since the hydrophobic region of the membrane
protein might not be completely covered. On the contrary, it is beneficial
to use a detergent with a shorter carbon tail during crystallization since it
will give room for forming crystal contacts between the hydrophilic regions
of the protein [119].
Figure 2.3: Detergent solubilization of membrane proteins. Detergent
(green), membrane protein (brown) and lipid bilayer (beige).
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2.3.2 Chromatography
Purification of solubilized membrane protein is most often performed in two
steps, the first being an affinity purification step and the second a size exclu-
sion chromatography step. During affinity purification the tag which is fused
to the target protein is interacting with a specific resin. Polyhistidine-tags are
commonly used and they have affinity for divalent metal ions like Ni2+ and
Co2+. The immobilized protein is eluted from the matrix by either changing
the pH or adding free imidazole to the elution buffer to compete with the
histidine-tag. By increasing the number of histidines in the polypeptide-tag,
inefficient binding to the metal ion matrix might in some cases be overcome.
After an affinity purification step the protein is often reasonably pure,
although it is often necessary to include a size-exclusion step as a last pol-
ishing step. During size-exclusion chromatography it is possible to check the
homogeneity of the protein as well as changing the buffer composition and/or
detergent if necessary.
2.4 Crystallization and structure determina-
tion
Protein molecules are small in comparison to what can be detected with
the naked eye. It is therefore necessary to use a technique which is able to
resolve the atomic structure, and thereby detect interactions between atoms.
Chemical bond distances are in the order of 1-3 Ångström (Å) and with X-
ray diffraction it is possible to detect atoms about 1 Å apart (1 Å = 10−10
m).
X-rays are electromagnetic radiation with a short wavelength (10−8-
10−12 m). When protein crystals are exposed to X-rays, a diffraction pat-
tern is generated from the interference between the electrons surrounding
the atoms and the X-rays. From the diffraction pattern the arrangement of
atoms within the protein crystal, i.e. the structure of the protein can be
calculated.
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2.4.1 Protein crystallization
An X-ray diffraction experiment requires protein crystals. Protein crystals
are built up by symmetrically arranged molecules in a three-dimensional
pattern. These crystals are often grown in vapor-diffusion experiments where
the protein sample is slowly dehydrated bringing the protein into nucleation,
leading to crystal formation (Figure 2.4).
Figure 2.4: Phase diagram for protein crystallization. Illustration of the
different zones involved in crystal formation. An ideal strategy for growing large
crystals is indicated by the two arrows.
Protein crystallization is affected by several variables: protein concentra-
tion, ionic strength (salt concentration), pH, temperature and precipitant
(e.g. polyethylenglycol - PEG). Protein crystals are held together with rela-
tively weak forces compared to inorganic crystals, which are held together by
electrostatic interactions of fully charged ions. The hydrogen bonds between
the protein and water molecules in the solvent makes the crystal more fragile
compared to an inorganic crystal.
Furthermore, membrane proteins have large hydrophobic regions cov-
ered by detergent micelles. As a consequence detergent-protein crystals are
packed in a type II crystal form, where the hydrophilic ends of the pro-
tein are involved in crystal contacts and a large solvent space (containing
detergents) surrounds the hydrophobic parts. There are alternative protein
crystallization methods available in addition to the above mentioned vapor-
diffusion method, e.g. membrane proteins can also be crystallized using the
lipidic-cubic phase (LCP) method [121]. LCP crystals are often packed in
the type I crystal form, where lipid monolayers are stabilized by hydrophobic
and hydrophilic interactions. Recently, it has also been demonstrated that
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it is possible to use LCP crystallization of membrane proteins which have
been solubilized by styrene-maleic acid (SMA) copolymers instead of deter-
gents [122]. SMA copolymers forms SMA nanodiscs when wrapped around
planar lipid bilayer fragments containing membrane proteins and their sur-
rounding lipids.
2.4.2 Structure determination using X-ray crystallog-
raphy
The process of structure determination using X-ray crystallography goes
through a number of steps:
• Collecting diffraction images.
• Identifying and integrating the reflections.
• Scale and merge the intensities.
• Solve the phase problem.
• Build and refine a model.
• Evaluate the model.
Diffraction is the interference of waves when a wave encounters an ob-
stacle or slit comparable in size with its wavelength. The diffraction pattern
which is observed when a crystal is exposed to X-rays is described by Bragg´s
law (Equation 2.1), where n is a positive integer, λ is the wavelength of the
incoming wave, d is the spacing between lattice planes and θ is the scattering
angle.
nλ = 2dsinθ (2.1)
The difference in intensity between measured reflections are related to
the atomic arrangement and the types of atoms in the unit cell. The unit
cell is the smallest repeating unit with translational symmetry within the
crystal. The structure factor Fhkl describes the amplitude |Fhkl| and phase
α of a wave diffracted from crystal lattice planes characterized by Miller
indices h,k,l. The electron density ρ(x,y,z) at a position x,y,z in the unit cell
is obtained by calculating the Fourier transform of the structure factor Fhkl
(Equation 2.2).
ρ(x, y, z) = 1
V
∑
h
∑
k
∑
l
|Fhkl|e−2pii(hx+ky+lz)+iα(hkl) (2.2)
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During an experiment it is only possible to experimentally measure the
intensities, which is proportional to |Fhkl|2, whereas the information regard-
ing the phase is not obtained; this is often referred to as the “phase problem”
of crystallography.
To obtain an electron density map of the protein structure, the phase
problem has to be solved. One of the most commonly used methods is molec-
ular replacement (MR) where the phases are calculated from a similar previ-
ously solved structure. In general a sequence identity of > 25% and an r.m.s.
deviation of < 2 Å between Cα atoms of the model and structure are re-
quired for a successful molecular replacement [123]. If MR does not solve the
phase problem, single- or multiple-wavelength anomalous diffraction (SAD
or MAD) can be used instead.
In a SAD experiment, heavy atoms have been incorporated into the pro-
tein structure at a limited number of sites, where they do not alter the actual
structure of the protein in its native form. These heavy atoms will give rise
to differences in the intensities of reflections that are related by inversion
symmetry [124]. The anomalous differences are used to locate the position
of the heavy atoms in the substructure and subsequently used for estimating
the phases of the entire structure [125]. Once the phases have been obtained
an electron density map can be calculated and a preliminary model can be
built. The obtained model is refined until agreement between the model and
the data is acceptable.
2.4.3 Validation of the data and the structure
During both data processing and model building there are a number of val-
idation parameters calculated. Although there are guidelines of where to
draw the line for a good data set and subsequently a good model it is worth
to note that the final value of validation parameters might deviate a bit.
The protein structural model is refined in an iterative process, evaluating
the calculated parameters, the model and the electron density map.
In a first step it is necessary to decide up to which resolution limit the
data should be used. The reflections observed in the higher resolution shells
tend be weaker than the rest of the data, which will affect the parameters
in a negative way. The signal to noise is described with I/σ(I), which is the
average ratio of reflection intensity to its estimated error.
The accuracy in the final estimation of the averaged reflection intensity
is better the higher the redundancy, since every reflection is measured with
a certain degree of error. Rsym, sometimes called Rmerge is a measure of the
spread of individual intensities of all symmetry-equivalent reflections. The
correlation coefficient CC1/2 divides the data in two randomly distributed
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sets and calculates the correlation between intensities in the two half data
sets. These parameters should also be monitored.
During the refinement process, Rwork and Rfree are calculated, which
are measures of the global relative discrepancy between the experimentally
obtained structure factor amplitudes and calculated structure factor ampli-
tudes obtained from the model. The calculation of Rfree is performed on a
small fraction of the complete data which has been omitted from refinement.
In this way over-interpretation of the data can be indicated. Local evaluation
of the model is done by examining the local fit of the model to the electron
density, evaluating the backbone torsion angles and bond lengths as well as
side chain conformations of the individual amino acids.
2.5 Characterization of protein activity and
the interaction with small-molecule ligands
In drug discovery, an important step is to determine the affinity between
a target molecule and its interaction partner. There are several methods
available for determining the affinity of a small-molecule ligand to the protein
of interest. However, all methods might not work for all proteins, and/or they
require a lot of optimization. In the following sub-chapter a few of these
techniques will be introduced.
2.5.1 Substrate transport across a bilayer
A membrane protein transporter transports its substrate over a lipid bilayer
without covalently modifying the substrate. During this process the trans-
porter undergoes conformational changes which alternately exposes the sub-
strate to either side of the membrane, a process which is generally more com-
plex than many enzyme systems. Through in vitro experiments the flux of
substrate mediated by the transporter can be characterized by the Michaelis-
Menten parameters KM and Vmax [126], a model initially developed to de-
scribe the enzyme conversion of substrate to product. For membrane protein
transporters the transport velocity reaches a plateau (steady-state) at high
substrate concentrations, where above this values there is no significant in-
crease in uptake rate. When all the substrate sites are occupied, the trans-
porter is saturated and the rate of transport is maximal, Vmax. From a plot
of transport velocity versus substrate concentration both Vmax and KM can
be determined. KM is the substrate concentration at which the reaction rate
is half of Vmax.
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2.5.2 Binding affinity
The strength of the interaction between a protein and its ligand/binding
partner (substrate/inhibitor/drug) is determined by the binding affinity.
Binding affinity is often reported as the equilibrium dissociation constant
Kd. In the following reaction (Equation 2.3), P is the protein, L is the ligand
and PL is the protein-ligand complex.
P + L
kon−−⇀↽−−
kof f
PL (2.3)
The rate constant is defined as kon in the forward direction and koff in
the reverse reaction. At equilibrium (Equation 2.4), the rate in both direc-
tions are equal hence:
[P ][L]kon = [PL]kof f (2.4)
This relationship is referred to as the law of mass action and the disso-
ciation constant Kd (Equation 2.5) describes this relationship as follows:
Kd =
kof f
kon
= [P ][L][PL] (2.5)
2.5.3 Microscale thermophoresis – MST
With microscale thermophoresis (MST) it is possible to determine the equi-
librium dissociation constant Kd in solution by taking advantage of the flu-
orescent signal of one of the binding partners.
Thermophoresis is the directed movement of molecules along a temper-
ature gradient. This physical principal depends on changes in size, charge
and solvation shell of molecules. During an MST-experiment the variation
in fluorescent signal of an immobilization-free molecule is measured. The
variation in fluorescent signal is a result of an induced temperature gradient
obtained by an IR laser. Furthermore, the variation in the fluorescent sig-
nal correlates with the binding of a non-fluorescent ligand to the fluorescent
binding partner. A local change in temperature ∆T leads to a local change
in molecule concentration (depletion or enrichment) [127].
In a serial dilution, the concentration of the non-labeled ligand is in-
creased so that the fraction of complex increases until all fluorescent molecules
have formed complex with the titrated ligand. As a result, the fraction of
bound molecules can be derived from the measured change in normalized
fluorescence. A binding curve can be obtained, from where the Kd can be
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determined, by plotting normalized fluorescence versus the concentration of
non-labeled ligand.
2.5.4 Fluorescence resonance energy transfer – FRET
Fluorescence resonance energy transfer (FRET) [128] is the non-radiative en-
ergy transfer from a donor to an acceptor chromophore. FRET occurs when
the emission and excitation spectra of the donor and acceptor chromophores
overlap, hence they need to be in close vicinity to each other (10-100 Å).
It is common to use two different chromophores as the donor and ac-
ceptor. In the MraY FRET assay the donor fluorophore is attached to the
substrate UDP-N -acetylmuramyl-pentapeptide (UNAM-pp). The donor flu-
orophore, BODIPY-FL, has an excitation wavelength of 485 nm and an
emission wavelength of 520 nm. The FRET acceptor lipid, lissamine rho-
damine B dipalmitotyl phosphatidylethanolamine (LRPE) has an emission
wavelength of 590 nm.
Figure 2.5: Schematic of the FRET assay used for determining MraY
activity. Detergent micelles (green) contain MraY (blue), undecaprenyl phos-
phate (C55P) (grey), FRET acceptor lipid (red) and UDP-N -acetylmuramyl-
pentapeptide (UNAM-pp) (purple) labeled with FRET donor (green) (B-UNAM-
pp). The FRET donor comes in close vicinity to the FRET acceptor upon transfer
of the labeled UNAM-pp to the C55P by MraY and UMP is released (not shown).
A reduction in donor fluorescence occurs during energy transfers from the FRET
donor to the FRET acceptor (yellow lightning bolt). Illustration inspired from [99].
The principal of the MraY FRET assay is illustrated in Figure 2.5. MraY
protein is embedded in a detergent micelle together with the lipid substrate
(C55P) and the FRET acceptor-labeled lipid (LRPE). Furthermore, this
is combined with the soluble FRET donor-labeled peptide substrate (B-
UNAM-pp). MraY catalyzes the transfer of the labeled soluble substrate
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B-UNAM-pp to C55P, which brings the FRET donor fluorophore in close
proximity to the FRET acceptor. Upon excitation of the donor fluorophore,
energy is transferred from the donor fluorophore to the acceptor fluorophore,
resulting in a decrease in donor fluorescence and potentially an increase in
acceptor fluorescence. The ratio change ∆(F590/F520) increases in size with
reaction time since the F520 intensity decreases due to the substrate being
converted to product and the F590 intensity is almost constant [99].
By adding an inhibitor, the FRET- assay can be used to determine the
IC50-values of potential inhibitors. The potency of a drug can be described
by the half-maximal inhibitory concentration (IC50). It is a measure of how
much drug is needed to inhibit a biochemical reaction by 50%.
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The main goal with the sialic acid transporter project was to determine the
structure of a sialic acid transporter, mainly focusing on the SiaT trans-
porter. In this process it is important to find suitable candidates for struc-
tural and functional studies. This chapter is divided into three sub-chapters
describing and discussing the results from Paper I - Paper IV. Chapter
3.1 presents the work from gene to pure protein (Paper I, Paper III and
Paper IV). In chapter 3.2 the structure of the first bacterial sialic acid
transporter SiaT from Proteus mirabilis (PmSiaT) is presented (Paper II).
Finally, in chapter 3.3 the bacterial growth assay used to characterize SiaT
is described (Paper I - Paper III).
3.1 From gene to pure protein
As with most membrane protein projects involving structure determination,
it all started with a set of genes. Adopting an orthologous approach is often
favorable to increase the chances of obtaining a construct suitable for struc-
ture determination. The empirical process of membrane protein production
and structure determination includes a number of bottlenecks which need to
be overcome.
3.1.1 Construct design and overexpression trials
For overexpressing membrane proteins, constructs are generated suitable for
the expression host. The sialic acid transporters under investigation have
their origin from bacterial organisms, hence the selected host for overex-
pression was the E. coli system. To increase the amount of overexpressed
protein, the genes encoding the target protein can be codon optimized for
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the selected expression host, to improve the protein translation efficiency af-
fected by codon bias [129]. This approach was applied for the selected genes
encoding sialic acid transporters.
Initially genes encoding SiaT were cloned into the pBAD-vector for titrat-
able expression of the recombinant protein through regulation of carbon
source [130]. Expression screening of SiaT was performed, varying L-arabinose
concentration using standard protocols. With the pBAD-system, it was pos-
sible to express SiaT although in very small amounts only detectable with
Western blot (data not shown). In contrast to SiaT, the pBAD expression
system was more suitable for one of the TRAP constructs (Pasteurella mul-
tocida TRAP) (Paper IV).
Topology prediction [131] of genes encoding SiaT was predicted to con-
sist of thirteen transmembrane helices with the N-terminal located on the
extracellular side and the C-terminal located on the intracellular side. A
set of seven SiaT genes from different bacterial organisms (Salmonella en-
terica servoar Typhimurium (Se), Staphylococcus aureus (Sa), Streptococ-
cus pneumoniae (Sp), Clostridium perfringens (Cp), Vibrio fischeri (Vf ),
Photobacterium profundum (Pp) and Proteus mirabilis (Pm)) were there-
fore cloned into the pWarf(-) vector, generating SiaT-GFP fusion constructs
(Paper I). Furthermore, additional constructs were generated for those SiaT
genes which were predicted to possess a disordered region within their C-
terminal [132]. The reason behind generating ∆SiaT-GFP constructs was to
be proactive and foresee any potential negative impact upon crystallization
since disordered regions often have a negative impact on the ability for a
protein to crystallize.
SiaT-GFP and ∆SiaT-GFP constructs were screened for overexpression
in the E. coli Lemo21(DE3) strain. The expression level was monitored by
measuring the relative fluorescence (RFU) (Paper I). The screening aimed
to find optimal temperature and an optimal concentration of L-rhamnose,
where the latter acts as an inducer for expression of T7 Lysozyme. T7
Lysozyme in turn inhibits T7 RNA polymerase and reduces the levels of
leaky expression from the T7 expression system [107] which could be toxic
for the host cell. Of the thirteen constructs aimed for test expression, two
were unsuccessfully cloned and one of these two was used as a negative con-
trol during test expression. For the remaining eleven constructs, all were
successfully expressed with varying expression yield (Paper I).
In contrast to SiaT, the TRAP sialic acid transporter was predicted to
have the C-terminal located on the extracellular side (Paper IV). The genes
encoding TRAP sialic acid transporters from P. multocida (Pm), Fusobac-
terium nucleatum (Fn), Vibrio cholera (Vc) and Haemophilus influenzae (Hi)
were cloned into both the pWarf(-) and pWarf(+) vector, where the latter
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harbors an additional Glycophorin A transmembrane helix which directs the
C-terminal of the protein into the intracellular side. The location of the C-
terminal is important since GFP is not able to fluoresce if situated on the
extracellular side. All pWarf(+) TRAP constructs except PmTRAP were
successfully expressed. Furthermore, FnTRAP and PmTRAP constructs in
pWarf(-) did not show any fluorescence, hence the topology prediction was
confirmed (Paper IV).
In general, expression at the lowest temperature tested (25°C) gave the
highest RFU values for SiaT-GFP and ∆SiaT-GFP fusion proteins, indi-
cating a higher expression yield. Lowering the temperature slows down the
protein expression process and allows the protein to be correctly folded and
inserted into the membrane [133]. The optimal temperature for expression
of the TRAP sialic acid transporters in the pBAD-system was determined
to 18°C (Paper IV).
Control of expression is a key factor for recombinant membrane protein
expression. Obtaining correctly folded and stable protein is important as a
first step towards crystallization experiments. The pWarf-system proved to
be successful for the SiaT constructs. In contrast, the pBAD-system was
more suitable for the TRAP sialic acid transporters.
3.1.2 Detergent screening using FSEC
Membrane proteins are embedded in a lipid bilayer and need to be extracted
upon purification. The natural lipid bilayer shields the hydrophobic regions
of the membrane protein. Amphipathic detergents extract the membrane
protein from their natural environment upon solubilization and covers the
hydrophobic regions. An optimal detergent is able to solubilize the membrane
protein efficiently and keep it in a functional conformation and prevent ag-
gregation.
Once expression of SiaT-GFP was established, a set of promising candi-
dates were screened for suitable detergent, using FSEC (Paper I). FSEC
relies on the incorporation of a fluorescent tag to the protein. With FSEC,
the elution profile of the SiaT-GFP fusion protein is monitored and eval-
uated. The method allows for screening of detergents in a relatively fast
and efficient way evaluating expression levels, degree of monodispersity and
approximate molecular weight of the fusion protein [134].
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In Paper I the initial detergent screening of three SiaT-GFP fusion pro-
teins (PmSiaT, SaSiaT and the third hereafter called XxSiaT) using FSEC
(Figure 3.1) is presented. The fluorescent elution profiles indicated monodis-
perse peaks for the majority of the detergents tested, although the width of
the peak varied between constructs and detergents. The smaller detergent
β-OG was not able to efficiently solubilize SiaT-GFP. The majority of the
β-OG solubilized sample was eluted close to/in the void volume indicating
aggregated sample.
The results from the FSEC profiles together with the efficiency for the de-
tergent to solubilize SiaT-GFP (RFU-values) were combined to rank suitable
detergents for solubilization and purification. The most promising detergents
identified for SiaT-GFP were the gentle maltoside detergents DM and DDM,
which differ from each other by the length of their carbon tail (C10 and C12,
respectively). DDM was selected as the best candidate for PmSiaT, and DM
was selected for SaSiaT and XxSiaT. The choice of detergent was further
examined and re-evaluated based on large-scale size-exclusion purification
profiles.
Figure 3.1: Detergent screening of SiaT from three different bacterial
organisms using FSEC. SiaT-GFP was solubilized from E. coli membranes
with different detergents and the soluble fraction was loaded onto a Superdex
200 10/300 GL column. Detergents tested: DDM (black), DM (blue), MNG12
(brown), MNG10 (orange), β-OG (green) and fc12 (pink). A) PmSiaT-GFP. B)
SaSiaT-GFP. C) XxSiaT-GFP.
In Paper IV the detergent screening using FSEC indicated that the
new class of detergents, maltose-neopentyl glycol (MNG) [135] was the most
promising for the TRAP sialic acid transporters. For VcTRAP and Pm-
TRAP (not evaluated using FSEC) this result agreed with detergent screen-
ing of constructs expressed in the pBAD-system as evaluated by Western-
blot.
36
3.1. From gene to pure protein
3.1.3 Purification of SiaT
Purification of SiaT follows mainly a two-step purification scheme (Paper
I). In the first affinity-purification step, the detergent-solubilized material
was immobilized onto a HisTRAP column (IMAC purification), washed and
eluted with an increased concentration of imidazole. Affinity purification is
often used as a first purification step since it specifically binds an accessi-
ble affinity tag which has been introduced during cloning. Purification was
monitored at 280 nm (measuring intrinsic fluorescence of proteins) and with
a fluorescence detector (excitation 485 nm and emission 512 nm) measuring
GFP-fluorescence.
The GFP-His-tag was removed from SiaT with HRV3C protease to in-
crease the chances of obtaining a stable protein sample suitable for crystal-
lization. HRV3C protease specifically cleaves the polypeptide at its recogni-
tion site, which is located after the SiaT protein and before the GFP-His-
tag. To separate the GFP-His-tag from the protein after cleavage, a reverse
IMAC step is often preferred since it allows for the affinity-tag to bind to the
resin while the target protein can pass through. Due to complete removal
of the GFP-His-tag by the HRV3C protease and the significant difference in
size, this additional purification step could be excluded from the purification
scheme and the tag was fully separated from the protein during size-exclusion
chromatography.
Size exclusion chromatography (SEC) separates molecules based on their
size, where small molecules travel a longer path through the porous station-
ary phase compared to large molecules which do not get delayed. As a final
step the protein was purified with size-exclusion chromatography to obtain a
monodisperse tag-free protein sample (Figure 3.2). Important characteristics
to evaluate during size-exclusion chromatography is the homogeneity of the
protein identified with a sharp Gaussian peak. Broad peaks often indicate the
presence of oligomers. In order to try and capture the substrate-bound form
of SiaT, the sialic acid Neu5Ac was included in the size exclusion buffer. The
substrate most likely also further stabilizes the protein during purification.
Even though the FSEC detergent screen and complementing RFU-
measurements of solubilized protein pointed towards using DM as detergent
for the SaSiaT construct (Paper I), large scale SEC purifications resulted
in a double peak profile. Hence the detergent was exchanged to DDM which
reduced the size of the first shoulder in the SEC profile (Paper III). Ana-
lytical ultracentrifugation experiments of SaSiaT concluded that SaSiaT can
be purified as a monomer in the presence of ∼200 DDM detergent molecules
(Paper III).
Establishing a purification protocol can be tedious. There are several
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Figure 3.2: Size-exclusion profiles of SiaT. A) Comparison of profiles for
PmSiaT and XxSiaT solubilized and purified with the detergent MNG12. XxSiaT
displays a narrower and more Gaussian shaped peak than PmSiaT. B) Comparison
of PmSiaT in the detergents MNG12 and DDM. The elution profile for PmSiaT
in the DDM detergent is more desirable than the MNG12-profile. In both A) and
B), the first peak at ∼50 mL is SiaT without any fusion-tag, peak 2 at ∼80 mL is
the free GFP-His-tag, peak 3 at ∼120 mL is impurities.
variables which can affect protein stability and purity. Incorporating a GFP-
fusion tag to the SiaT protein proved to be successful. The GFP-fusion tag
allowed for expression screening in a much faster and reliable way. Further-
more the advantage with having a fluorescent tag allowed for detergent-
screening and re-evaluation of the monodispersity and purity in subsequent
purifications. PmSiaT was selected as the top candidate for crystallization
studies, based on expression-level and SEC profile.
3.1.4 Crystallization of SiaT
Hydrophilic interactions is an important force for the formation of protein
crystals. Since membrane proteins are surrounded by a detergent micelle,
the possibilities for hydrophilic interactions are limited, and the choice of
detergent affects the size of the protein-detergent complex. In Paper I the
conditions obtained from conventional crystallization screens which resulted
in crystal formation of PmSiaT using hanging-drop vapor diffusion exper-
iments are described. Furthermore, optimization of crystal conditions by
performing grid screens, resulted in crystals which diffracted beyond 3 Å
resolution.
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3.1.5 Summary
In chapter 3.1 the path from construct design and cloning of sialic acid
transporters to purification and crystallization yielding SiaT crystals, which
diffracted beyond 3 Å resolution has been described. Adopting an ortholo-
gous approach for identifying suitable constructs for crystallization of SiaT
and TRAP sialic acid transporters and structure determination of SiaT
proved to be successful. Reasonable overexpression levels of SiaT were iden-
tified in the titrable E. coli Lemo21(DE3) strain at low temperatures. Fur-
thermore, the GFP-fusion tag facilitated detection of expression levels and
evaluation of detergents for the SiaT constructs.
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3.2 The crystal structure of PmSiaT
In Paper II the first structure of a sialic acid transporter, SiaT from P.
mirabilis (PmSiaT) is reported. The Gram negative uropathogen P. mirabilis
is able to catabolize host derived sialic acids as a source of nutrient. The
structure of PmSiaT was determined at 1.95 Å resolution, using X-ray crys-
tallography, in its outward-open conformation with the substrate Neu5Ac
and two Na+ ions bound (Na2 and Na3) (Figure 3.3).
3.2.1 Data collection and structure determination
Optimized crystals of PmSiaT (Paper I) allowed for data collection of a
native data set of PmSiaT with diffraction to 2.26 Å resolution (Paper II).
Several attempts to obtain the phases with molecular replacement (MR)
using LeuT-like structures as search models were unsuccessful. Hence the fo-
cus shifted towards the selenomethionine (SeMet)-approach, incorporating
heavy atoms into the protein structure without changing its conformation.
Selenomethionine replaces methionine residues in the protein when the pro-
tein is expressed in a medium containing selenomethionine as the sole source
of methinonine. SeMet-incorporated crystals were obtained in similar crys-
tallization conditions as for the native data set, with 1% OG and 20 mM
Neu5Ac added to the reservoir. Several data sets of SeMet crystals were col-
lected although none had high enough redundancy for the overall individual
data sets. The phases were obtained by merging thirteen SeMet data sets
(Paper II).
3.2.2 Overall structure of PmSiaT
In agreement with topology prediction, SiaT comprises of thirteen transmem-
brane helices (TM0 and TM1-TM12) with the N- and C-termini facing the
extracellular side and intracellular side respectively (Figure 3.3). PmSiaT is
captured in a substrate and sodium bound outward-open conformation [136].
SiaT belongs to the SSS-family and adopts the LeuT-fold [14, 137], where
two inverted repeats (TM1-TM5 and TM6-TM10) forms the structural core
of the protein (Figure 3.3B). The four-TM helix bundle (core domain) con-
sists of the first two helices from each repeat TM1-TM2 and TM6-TM7,
the hash domain (scaffold domain) consists of the third and fourth helix of
each repeat TM3-TM4 and TM8-TM9 and the two peripheral arms (gating
helices) correspond to the fifth helix of each repeat TM5 and TM10.
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Figure 3.3: The structure of PmSiaT in its outward-open sialic acid
and sodium ion bound conformation. A) The PmSiaT structure is colored
from N- to C-terminus (blue, red, and yellow to green), Neu5Ac (purple) is dis-
played as sticks colored by atom and the two sodium ions are displayed as spheres
(grey) (PDB ID: 5NV9). The lipid membrane is indicated with grey lines. B)
Structural elements that characterize the LeuT-fold of PmSiaT are displayed.
The four-TM helix bundle/the core domain (TM1-TM2 and TM6-TM7 (beige)),
the hash-/scaffold domain (TM3-TM4 and TM8-TM9 (purple)) and the two pe-
ripheral arms/the gating helices (TM5 and TM10 (green)). Additional helices not
part of the main LeuT-fold are colored in pink. All transmembrane helices are
numbered (0, 1-12).
3.2.3 Sialic acid binding site
Near the center of the protein, residues from four helices (TM1-TM3 and
TM6) line the sialic acid binding site, including the discontinuous helices
(TM1 and TM6) which are important for substrate binding. Discontinuous
helices play an important role in the alternating access mechanism [21, 22,
137,138].
In the sialic acid binding pocket, the β-anomer of Neu5Ac is coordinated
by eight amino acid residues and seven water molecules (Figure 3.4). Three
residues from TM1 (Thr58, Ser60 and Thr63) form both side- and main
chain hydrogen bonds with Neu5Ac. More specifically, Ser60 and Thr63 co-
ordinate the negatively charged carboxylate group (at C1), whereas Thr58
and Thr63 coordinate hydroxyl groups from the glycerol tail. In addition,
Thr58 coordinates the hydroxyl group at the C2 position. The carboxylate
group of Neu5Ac also makes a salt bridge interaction with the neighboring
guanidinium group of Arg135 (TM3). Interaction between a basic amino acid
residue and a sugar molecule has been observed previously in vSGLT [21].
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Furthermore in the soluble sialic acid binding protein SiaP, sialic acid inter-
acts with a conserved arginine which is important for high affinity substrate
recognition by the sialic acid TRAP transporter [139]. Additional hydrogen
bonds between a hydroxyl moiety of the glycerol tail is observed with Gln82
(TM2). Amino acids Phe78, Gly81 (TM2) and Phe243 (TM6) create a re-
gion with a neutral electrostatic surface which surrounds the acetyl amino
moiety of the Neu5Ac methyl group.
Several water-mediated interactions are observed in the hydration layer
which occupies the space between Neu5Ac and TM5-TM6. The amino acid
residues Gln82, Phe78 (TM2) and Asn247, Gln250 (TM6) all participate in
water-mediated interactions with Neu5Ac.
Figure 3.4: The sialic acid binding site of PmSiaT. Neu5Ac (purple) is
represented as sticks colored by atom and water molecules are represented as
spheres (red). Neu5Ac forms interactions with amino acid residues from TM1-TM3
and TM6, including water-mediated hydrogen bonds with amino acid residues from
TM2 and TM6 (PDB ID: 5NV9).
3.2.4 Characterization of the sialic acid binding site
The ability of SiaT to transport the sialic acid Neu5Ac was demonstrated
with proteoliposome experiments. In these experiments the purified SiaT-
transporter was inserted into an artificial bilayer. After reconstitution, a
potassium ion diffusion potential was generated by adding valinomycin. Vali-
nomycin is a lipid-soluble molecule which selectively binds potassium ions
and facilitates their transfer across lipid bilayers. Upon the addition of ra-
diolabeled substrate in the presence of sodium ions, the co-transport was
initiated. Transport was terminated by removing the excess of substrate
and measuring the radioactivity of the radioactive substrate which had been
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transported into the proteoliposomes. Single mutations of amino acids which
make side chain interactions with Neu5Ac (Thr58Ala, Ser60Ala, Thr63Ala,
Gln82Asp and Arg135Glu) were designed to disrupt the transport. All ex-
cept Thr58Ala, where Thr58Ala coordinates the anomeric hydroxyl at the C2
position of Neu5Ac through a main chain interaction, abolished transport.
Through proteoliposome experiments the maximal transport activity was
determined to 1800 nmol/mg protein (0.4 nmol). In addition, Vmax (187 ±
30 nmol/mg protein/min) and KM (16 ± 4 µM) could also be determined.
Furthermore, the binding affinity (Kd) between sialic acid and PmSiaT was
determined with isothermal titration calorimetry (ITC) and microscale ther-
mophoresis (MST) (Table 3.1).
Table 3.1: The binding affinity constant Kd between PmSiaT and different sialic
acid derivatives. Kd was determined by MST and ITC (for Neu5Ac).
Kd
Neu5Ac Neu5Gc KDN
MST 58 ± 1 µM 85 ± 2 µM >10 mM
ITC 50 ± 4 µM − −
The observed difference between Kd and KM for Neu5Ac can possibly be
explained by experimental differences. In a proteoliposome experiment the
protein is embedded in a lipid bilayer in contrast to the detergent micelle
which surrounds the protein in the ITC and MST experiments.
3.2.5 Sodium binding sites
In an electron density map it can be difficult to distinguish sodium ions from
water molecules [140]. However, there are distinguishing features of sodium
ion binding sites. Sodium ions coordinate with 4-8 partners and the bond
distances are less than 2.7 Å [141]. In the PmSiaT structure two sodium
binding sites were observed. One sodium ion was modeled in the conserved
Na2 site [22] in a protruding kink in TM1 and interestingly the second sodium
ion was modeled in a unique position termed Na3 between TM1 and TM8
(Figure 3.5).
In proteins with the LeuT-fold, the Na2 sodium binding site is highly
conserved and is mainly formed by residues from the first helix of the first
repeat and the third helix of the second repeat (TM1 and TM8) [15]. This is
consistent with the Na2 site of PmSiaT where the sodium ion in the Na2 site
is coordinated by the carbonyl oxygen atoms of Ala56 and Leu59 (TM1), the
hydroxyl groups of Ser342 and Ser343 (TM8) and the main-chain of carbonyl
oxygen of Ala339 (TM8).
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The sodium ion at the Na3 site is not in contact with the substrate, nor
close to the Na1 or Na1´sites, which are present in some transporters with
the LeuT-fold (described in chapter 1.3.2). The Na3 site is located further
6.5 Å towards the cytoplasmic side compared to the Na2 site. This is ∼14
Å away from the sialic acid binding site. The sodium ion at the Na3 site
is coordinated by the main-chain carbonyl group of Ser342, the hydroxyl
groups of Ser345 and Ser346 (TM8) and by the carboxyl group of Asp182
(TM5). In the electron density map there are clear density peaks for both the
Na2 and Na3 sites, no negative electron density was observed when modeling
a sodium ion in these sites. Both sodium ions coordinate five atoms and the
bond distances are in the range of 2.2 to 2.5 Å.
Figure 3.5: Sodium binding sites in PmSiaT. A) Illustration of the location
of Na2, Na3 and the substrate binding site in PmSiaT. Sodium ions are illustrated
as spheres (grey) and Neu5Ac (purple) as sticks colored by atom (PDB ID: 5NV9).
B) The Na2 and Na3 sodium binding sites. Amino acid residues interacting with
the sodium ions (grey) are represented as sticks, colored by atom.
3.2.6 Characterization of the sodium binding sites
How important are these sodium sites for the transport of sialic acid? It is
known from previous studies of LeuT that when a sodium ion is bound to
the Na2 site it stabilizes the structure in the substrate binding pocket [15].
Hence binding of sodium in the Na2 site is required for substrate binding.
In the proteoliposome assay (Figure 4c, Paper II), the single mutants
Ser342Ala and Ser343Ala of the Na2 site both abolished sialic acid transport.
This demonstrates the importance of the Na2 site for sialic acid transport
of SiaT. Even though the sodium ion in principal would be able to bind by
coordinating the remaining four amino acids, it is believed that the struc-
tural rearrangement, which occurs upon sodium binding, are important for
directing/positioning the sialic acid in its binding pocket. Molecular dynamic
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(MD) simulations of different states further shed light on the different roles
of the sodium binding sites. The sodium sites and the substrate binding site
are connected through a network of amino acids. In the crystal structure,
Ser342 coordinates both the sodium ion at the Na2 and Na3 sites. In addi-
tion, the Na2 site is further connected to the substrate binding site through
Leu59 which is located within the unwound segment of TM1 next to Ser60
which coordinates with the carboxyl group of Neu5Ac. In the MD simula-
tions, Ser60 is stabilized and able to maintain a bidentate interaction with
the carboxylate group of Neu5Ac due to interactions between the neighbor-
ing Leu59 and the sodium ion at the Na2 site. In the absence of sodium at the
Na2 site Neu5Ac is less stable in the MD simulations, further strengthening
the importance of the Na2 site.
When taking a closer look at the Na3 site, the single mutations Ser345Ala
and Ser346Ala of the Na3 site did not abolish sialic acid transport in the
proteoliposome experiments. However, Asp182 which has a bidentate co-
ordination with the sodium ion at the Na3 site abolished transport when
mutated to Ala. These results suggest that the binding of a sodium ion at
the Na3 site still is possible if the coordination is at least four. The presence
of a sodium ion at the Na3 site stabilizes the transporter in its outward-open
conformation and facilitates import of sialic acid.
It has been demonstrated that a sodium ion at the Na2 site in LeuT
causes an amplification of the selectivity toward sodium at the Na1 site [142].
This suggests that the order of binding would start with sodium binding to
the Na2 site before the Na1 site. This is also logical since the Na1 site is
located further towards the extracellular side in LeuT. However, the Na3
site in SiaT is located on the opposite side of Na2, closer to the cytoplasmic
side. The location of the Na3 site would suggest that sodium binds first
to the Na3 site, followed by sodium binding to the Na2 site and sialic acid
binding to the substrate site. MD simulations demonstrate how a sodium ion
in the Na2-only simulation results in movement of the sodium ion towards
the Na3 site. In the Na2-Neu5Ac simulation, the sodium ion is stable in the
Na2 position, highlighting the importance of the Na2 site upon substrate
binding.
What about the stoichiometry? Cooperativity of ligand binding in a pro-
tein is described by the Hill coefficient where a cooperative relationship be-
tween ligand binding sites is indicated with a Hill coefficient > 1. In SiaT,
the sodium transport is cooperative (Hill coefficient = 1.5 ± 0.1). With
a sodium:substrate stoichiometry of 2:1, the net transport is one positive
charge.
Is the Na3 site conserved? The stoichiometry and presence of sodium
binding sites in protein structure with the LeuT-fold vary, apart from the
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conserved Na2 site. The newly identified Na3 site is present in 19.6% of
analyzed SSS sequences, which also contains the Na2 site. However, it is
not present in the closely related protein families, neurotransmitter sodium
symporter (NSS), betaine/choline/carnitine (BCC) and nucleobase-cation-
symport (NCS1) which all have hydrophobic residues at this site.
Interestingly there are differences between secondary transporters which
adopts the LeuT-fold, concerning their stoichiometry and location of sodium
sites. The PmSiaT structure is the first characterized structure with a Na3
site, located on the opposite side of Na2 compared to the Na1 site. This
novel Na3 site enhances the substrate-binding affinity and structurally aids
in the stabilization of the outward-facing conformation of SiaT.
3.2.7 Alternating access of SiaT
Secondary transporters transport solutes across a lipid bilayer in the co-
transport of the driving ion(s). The transporter alternates access to the bind-
ing sites by adopting a set of different conformations in the transport cycle.
The newly determined crystal structure of PmSiaT, adopts an outward-
facing open conformation with both the substrate and sodium ions bound.
In an attempt to explore the overall transport mechanism, an inward-facing
model of PmSiaT was built based on the structure of vSGLT, which adopts
an inward-facing conformation [21] and morphs between the two states was
generated.
The extracellular open compartment of PmSiaT closes upon movement
of the N-terminal of TM10 towards TM1e and TM2. The movement fur-
ther directs TM9 towards TM3 and the extracellular loop helices Elh7a and
Elh7b (connecting TM7 and TM8), collapses into the open compartment and
interact with TM1e. A hydrophobic gate consisting of amino acids Trp404
(loop TM9-TM10), Ile67 (TM1) and Phe78 (TM2) occupy the space above
the substrate binding site. In a closed conformation the outer gate is sta-
bilized by hydrogen bonds between residues from the loop connecting TM9
and TM10 (Ala401 and Glu402) and Thr312 (Elh7) and Thr73 (TM1e) re-
spectively.
On the inside, the inner hydrophobic gate (the intracellular loop/helix
Ilh0) that occludes the substrate from the cytoplasm moves away and opens
the transporter by breaking the hydrogen bonds which initially are formed
with residues from the intracellular loop between TM4i and TM5. As Ilh0
moves away from the inner pore, the cytoplasmic ends of TM8 and TM9
participate in the opening and rearrange by moving away from the cavity.
Salt bridges between Glu176 (loop between TM4i-TM5) and the two arginine
residues Arg31 and Arg44 (Ilh0) are stabilizing the inner gate in its closed
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conformation. Interestingly, Arg40 of the intracellular gating loop/helix (Ilh0)
aligns with Arg5 in LeuT, which has previously been assigned to be involved
in intracellular gating [17].
In addition, the conserved Arg260 (TM6) in SiaT is located below the Na3
site and interacts with Ser53 (TM1), Asp256 (TM6) and Ser346 (TM8) in the
closed conformation. Based on proteoliposome experiments of the Asp260Glu
mutant, which did not exhibit any uptake of Neu5Ac, it is possible that the
side chain of the glutamic acid prevents the release of sodium ions and hence
abolish the transport of Neu5Ac.
3.2.8 Summary
In chapter 3.2, the first determined X-ray structure of a sialic acid trans-
porter, PmSiaT, is presented. PmSiaT adopts the LeuT-fold with two in-
verted repeats of five transmembrane helices, in an outward-open conforma-
tion bound to Neu5Ac at the substrate binding site and two sodium ions,
one at the conserved Na2 site and one at the novel Na3 site.
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3.3 Characterization of SiaT
3.3.1 SiaT is able to rescue the growth of E. coli ∆nanT
In order to investigate the functionality of SiaT used in the orthologous
approach for identifying a suitable construct for structure determination
(chapter 3.1), a whole cell bacterial growth assay [51] was performed (Paper
I).
E. coli can use sialic acid as a carbon and nitrogen source [49]. By using an
E. coli ∆nanT deletion strain, an E. coli strain which lacks the gene encoding
the native sialic acid transporter NanT, in combination with sialic acid as
the sole carbon and nitrogen source, it is possible to identify functional sialic
acid transporters. If the sialic acid transporter is functional, it will transport
the sialic acid into the cytoplasm where it can be further degraded and used
as nutrition for the bacteria.
Seven genes predicted to encode SiaT (mentioned in chapter 3.1.1) and
the gene encoding NanT from E. coli (EcNanT) were all cloned into a low-
copy vector and transformed into the E. coli ∆nanT knockout strain (E.
coli JW3193 ∆nanT [143]) and grown on minimal media supplemented with
Neu5Ac as the sole carbon source (Paper I).
The NanT transporter of E. coli [51] was used as a control in these ex-
periments. All seven SiaTs were able to rescue the growth of E. coli ∆nanT
when grown on minimal media supplemented with Neu5Ac as the sole car-
bon source (Figure 3.6) (Paper I). Furthermore SeSiaT had already been
characterized [51] and was used as an additional positive control in these
experiments. This bacterial growth experiment was important in the in vivo
characterization of the predicted SiaT transporter. With this type of ex-
periment it was not only possible to determine the functionality, it is also
possible to use the setup to investigate preference for different sialic acid
derivatives (discussed in Paper I and Paper III).
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Figure 3.6: Bacterial growth experiments of predicted SiaT from seven
different bacterial organisms and E. coli NanT. SiaT is able to rescue the
growth of the E. coli ∆nanT strain using Neu5Ac as the sole carbon and nitrogen
source. The black growth curve represents the predicted SiaT transporter grown on
minimal media supplemented with Neu5Ac. The brown growth curve represents
the E. coli JW3193 ∆nanT strain transformed with empty vector (used as a
negative control) grown on minimal media supplemented with Neu5Ac and the
blue growth curve represents the predicted SiaT transporter grown on minimal
media without Neu5Ac. Growth curves represent the mean of six replicates ±
SEM for EcNanT, PmSiaT, PpSiaT, SaSiaT, SeSiaT, SpSiaT and five replicates
± SEM for CpSiaT and VfSiaT.
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3.3.2 Characterization of PmSiaT
In Paper II we demonstrate how PmSiaT is able to rescue the growth of the
E. coli ∆nanT strain when grown on M9 minimal media supplemented with
Neu5Ac as the sole carbon source. In this experiment thiamine hydrochlo-
ride (Vitamin B1) had been added to the growth media to aid in catabolism.
The optimized growth media resulted in a higher optical density compared
to initial experiments. An additional positive control was included in these
experiments, namely the wild type E. coli BW25113 strain [144]. Expression
of NanT and SiaT was induced with IPTG. The growth lag observed com-
pared to the E. coli wild type strain could be related to the IPTG induction.
In the native E. coli strain, Neu5Ac is catabolized by five enzymes encoded
by the nan operon (including NanT) [49–51,145,146]. The genes are induced
by the presence of Neu5Ac in the growth medium through the loss of repres-
sion via the NanR protein [49, 145, 147]. In Figure 2A Paper II, there is
a lag between when the native E. coli strain and the deletion strain starts
their exponential growth phase. The lag could be a result of the difference in
induction of the two systems and/or an increased metabolic burden caused
by the overexpression of SiaT itself.
3.3.3 Sialic acid specificity between bacterial organisms?
The growth rates of SiaT from the seven different bacterial organisms, when
grown on Neu5Ac, are overall relatively equal (Paper I). However, CpSiaT
displays a reduced growth rate compared to the other SiaTs investigated
(Table 2, Paper I). The difference in growth rate might be a result of
differences within the sialic acid binding site, hence allowing for different
sialic acid derivatives to bind to the transporter with altered specificity.
In an attempt to visualize these differences, a homology model of CpSiaT
was build based on the PmSiaT structure (PDB ID: 5NV9) [136]. When
comparing the amino acids within 5 Å of the sialic acid binding site, the
majority of the differences were identified close to the acetyl amino group
at the C5 position and surrounding the glycerol chain at the C6 position of
Neu5Ac. It is within these regions of sialic acid where modifications often
occur [148].
3.3.4 Identifying sialic acid specificity in SaSiaT
Growth of E. coli on Neu5Ac and Neu5Gc requires the catabolic enzymes
which converts sialic acid to ammonia and fructose-6-phosphate [49,145,149].
Knowing this enabled evaluation of whether SaSiaT was able to transport
both Neu5Ac and Neu5Gc. In Paper III it is demonstrated how SaSiaT
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is able to rescue the growth of E. coli ∆nanT grown on either Neu5Ac or
Neu5Gc as the sole carbon source [150]. Interestingly, the growth rate is
faster when the media is supplemented with Neu5Gc (1.9 ± 0.05 x 10−3
rate/min) compared to Neu5Ac (1.3 ± 0.3 x 10−3 rate/min). In Paper III
it is speculated how this difference in growth rate can be related to the
difference in amino acids within the substrate binding site of SiaT.
Characterization of SaSiaT
The increased growth rate for SaSiaT grown on Neu5Gc compared to Neu5Ac
raised the question regarding substrate specificity. To investigate the poten-
tial difference in substrate specificity compared to PmSiaT, a combination
of binding studies and structural comparison based on the PmSiaT structure
were performed (Paper III).
Both MST and ITC measurements of the affinity of SaSiaT for the sialic
acids, demonstrated higher affinity for Neu5Gc compared to Neu5Ac. With
MST the Kd of SaSiaT was determined to 39 ± 4 µM and 113 ± 6 µM for
Neu5Gc and Neu5Ac, respectively. Comparing with the Kd of PmSiaT (85
± 2 µM and 58 ± 1 µM for Neu5Gc and Neu5Ac, respectively) (Paper II),
SaSiaT presents a higher affinity for Neu5Gc compared to Neu5Ac, which is
the opposite relationship found in PmSiaT. These binding studies are in line
with the in vivo bacterial growth assay that demonstrated increased growth
rate for SaSiaT when grown on Neu5Gc compared to Neu5Ac.
The hypothesis that SaSiaT has altered substrate specificity compared
to PmSiaT was further strengthened by comparing the KM of [3H]Neu5Ac
transport in SaSiaT (42 ± 9 µM) with PmSiaT (16 ± 4 µM) using a prote-
oliposome assay (Figure 5, Paper III).
Substrate binding site comparison between PmSiaT and a model
of SaSiaT
Is it possible to explain the difference in substrate specificity at a molecular
level? What are the differences between the SaSiaT and PmSiaT amino acid
sequences in the substrate binding site? In Paper II we concluded that the
overall amino acid sequence in the substrate binding site is conserved among
bacterial species (Figure 3, Paper II). A homology model of SaSiaT based
on the PmSiaT structure (PDB ID: 5NV9) was constructed (Paper III).
Three of the amino acids which differ between SaSiaT and PmSiaT (Asn83,
Asn244, Tyr79 in SaSiaT aligned with Gln82, Phe243, Phe78 in PmSiaT)
could potentially be responsible for the substrate specificity.
The difference between Neu5Ac and Neu5Gc is a hydroxyl group at the
C11 position (Figure 1.3). Most likely, the difference in affinity between
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Figure 3.7: Superposition of the SaSiaT homology model and the struc-
ture of PmSiaT. SaSiaT is colored in green, PmSiaT (PDB ID: 5NV9) in grey
and Neu5Ac (purple) is displayed as sticks colored by atom. A water molecule
from PmSiaT is displayed as a red sphere. Amino acids are labeled according to
SaSiaT with PmSiaT labels in italic. Black dashed lines illustrate interactions
between Neu5Ac and the corresponding amino acids. Figure adapted from [150].
SaSiaT and PmSiaT toward the two sialic acids is connected to the amino
acid differences mentioned above. In Paper III we speculate about how
the shorter side chain of Asn83 (SaSiaT) compared to Gln82 (PmSiaT)
will free more space in the substrate binding site and give room for the
additional hydroxyl group of Neu5Gc. Furthermore, the hydrogen bonds be-
tween Gln82 (PmSiaT) and the two hydroxyl groups at C7 and C9 might
still be possible, although with a longer bond length. It is also possible that
the additional hydroxyl group at C11 could hydrogen bond with Asn244
(SaSiaT) in a new interaction. The Tyr79 (SaSiaT) creates a more hy-
drophilic environment towards the extracellular side, which might be impor-
tant for discriminating between Neu5Ac and Neu5Gc. Previous studies have
demonstrated that some bacteria can discriminate between different sialic
acids [151–154]. It is also known that humans cannot synthesize Neu5Gc.
However, humans can metabolically incorporate Neu5Gc from red meat and
milk in their diet [151, 155–158]. In Paper III we demonstrate how the
sialic acid transporter SaSiaT has higher affinity towards the non-human
synthesized Neu5Gc compared to Neu5Ac.
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3.3.5 Summary
In chapter 3.3 the bacterial growth assay used in Paper I - Paper III has
been described. All genes which were predicted to encode SiaT (presented
in chapter 3.1) were able to rescue the growth of an E. coli ∆nanT strain
when grown on minimal media supplemented with Neu5Ac as the sole carbon
and nitrogen source. Furthermore, the assay was used in combination with
sequence alignments and a homology model of CpSiaT to speculate about
substrate specificity between SiaTs (Paper I). A preference for Neu5Gc
compared to Neu5Ac, in terms of growth rates of SaSiaT, was further con-
firmed by binding studies (Paper III). The bacterial growth assay of SiaT
is a helpful tool in exploring the sialic acid specificity in different bacterial
organisms.
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MraY
The overall goal with the MraY project is to generate X-ray crystal structures
of MraY in complex with potential inhibitors combined with biophysical
characterization for the future development of antibacterial drugs. In Paper
V the focus has been to structurally compare and analyze published MraY
and GPT structures to identify key features and propose structural motives
for future design of tunicamycin analogues which selectively targets MraY.
In Paper VI, the interaction between MraY and tunicmaycin analogues has
been biophysically characterized. The following chapter is divided into two
sub-chapters describing the findings from Paper V and Paper VI.
4.1 MraY - a structural comparison
In 2013 the first crystal structure of the bacterial membrane-bound enzyme
involved in peptidoglycan synthesis, MraY, was published [93]. MraY from
the Gram negative thermophilic bacterium A. aeolicus (Aa) was crystallized
in its apo conformation at a resolution of 3.3 Å. A few years later the apo
AaMraY structure was followed by the structure of AaMraY in complex
with the natural product inhibitor MD2, at a resolution of 2.95 Å [159]. The
structure of MraY from the Gram positive pathogenic bacterium Clostrid-
ium bolteae (Cb) in complex with the natural product inhibitor tunicamycin
(Tun) is the most recent structure of this membrane-bound enzyme and it
was determined at 2.6 Å resolution in 2017 [94] within this project before I
joined. As part of Paper V, structural similarities and differences between
the published structures of MraY (Table 4.1) were analyzed.
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Table 4.1: Structures of the bacterial membrane-bound enzyme MraY.
The structures are listed in order of released to the Protein Data Bank (PDB).
Protein-Ligand PDB ID Resolution (Å)
AaMraY-apo [93] 4J72 3.3
AaMraY-MD2 [159] 5CKR 2.95
CbMraY-Tun [94] 5JNQ 2.6
4.1.1 Structure of MraY
MraY consists of ten transmembrane helices (TM1-TM10) with both the N-
and C-terminus located on the periplasmic side (Figure 4.1A). The main
differences between the overall structures of AaMraY and CbMraY are the
additional periplasmic helix located between TM6 and TM7 as well as a more
defined periplasmic β-hairpin in the AaMraY structure (Figure 2B, Paper
V). In all crystal structures of MraY, a highly conserved glycine residue
(Gly258 CbMraY, Gly293 AaMraY) breaks TM9 into two helical segments
(TM9a and TM9b). This break results in TM9b being bent ∼50° relative
to the membrane and protrudes ∼20 Å into the lipid bilayer away from the
main structure. Helix 9c is a 11-residue helix located on the cytoplasmic side
between TM9b and TM10 which is important for substrate selectivity due to
the HHH-motif (His290, His291, His292 CbMraY) [160]. In the apo AaMraY
structure helix 9c is not clearly visible.
MraY catalyzes the synthesis of C55-PP-MurNAc-pentapeptide (lipid I)
at the cytoplasmic side of the lipid bilayer. The active site is composed of
the amphiphilic helix 9c, TM5-TM10 and loops C and D. A comparison of
the active site of the three structures of MraY reveals a significant differ-
ence between the apo and the two ligand-bound complexes, where the apo
AaMraY structure lacks a well-defined binding pocket.
The aspartic acid triad Asp93, Asp94 and Asp231 (CbMraY) is strictly
conserved within the PNPT superfamily and important for the enzymatic
activity of MraY [101]. The MraY catalysis is dependent on Mg2+ ions [90].
Both Asp93 and Asp94 (Asp115 and Asp116 in EcMraY) were proposed to
coordinate the Mg2+ ion, based on sequence similarity. In the apo structure
of AaMraY, Asp265 (Asp231 in CbMraY) coordinates a Mg2+ ion, whereas
in the AaMraY-MD2 and CbMraY-Tun structures, no Mg2+ ion is observed.
In the CbMraY-Tun structure, the ligand is interacting with Asp231, whereas
in the AaMraY-MD2 structure there is no interaction between Asp265 and
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MD2. Tunicamycin and Mg2+ are not able to interact with the enzyme
simultaneously [94], furthermore MD2 does not require Mg2+ for binding
MraY [159].
Figure 4.1: Structure of MraY. A) Overall structure of MraY (colored from N-
terminal (light blue) to C-terminal (dark blue) (PDB ID: 5JNQ) in complex with
tunicamycin (orange) colored by atom. The lipid membrane is indicated by grey
lines and transmembrane helices (TM) are labeled, water molecules are colored
in red. B) A close-up view of the active site. The CbMraY (blue)- Tun (orange)
complex is superimposed with the AaMraY (white)- MD2 (green) complex (PDB
ID: 5CKR). Amino acids within 5 Å of the ligands are shown as sticks and num-
bered according to CbMraY (except for K70 which only is modeled in AaMraY).
Figure modified from [85].
4.1.2 Interactions between MraY and the natural prod-
uct inhibitors
Both the tunicamycin and MD2 ligands share a common uridine motif (Fig-
ure 1.7) with the soluble substrate UDP-MurNAc-pentapeptide (Figure 1.8).
The uracil part of the two inhibitors are partially overlapping in the MraY-
complex structures; amino acids Gly176, Asn221 and Phe228 in CbMraY
(Gly194, Asn255 and Phe262 in AaMraY) create a small pocket for the
uracil motif. Coordination between the uracil ring and the enzyme occurs via
Asn221 and Asp178 as well as backbone interactions with Leu177 in CbM-
raY (Asn255, Asp196 and Leu195 in AaMraY). The phenylalanine Phe228
in CbMraY (Phe262 in AaMraY) is conserved throughout the PNPT su-
perfamily and in MraY it interacts with the uracil base via a π-π stacking
(Figure 4.1B).
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The three conserved histidines in MraY, denoted as the HHH-motif, are
located within the amphiphilic helix 9c. These histidine residues, His290,
His291 and His292 in CbMraY (His324, His325, His326 in AaMraY), form
interactions with both the tunicamycin and MD2 ligand. The GlcNAc ring
of tunicamycin interacts with His291 in CbMraY and the guanidine motif of
the peptidic moiety of MD2 interacts with His325 in AaMraY. Furthermore,
His324 and His325 of AaMraY interact with a carbonyl of the peptidic moiety
of MD2.
In contrast to tunicamycin, MD2 is split into two arms at the 5´-hydroxyl
group: the 5´-aminoribosyl and the peptidic moiety (Figure 1.7). In AaMraY
the 5´-aminoribosyl moiety of MD2 stretches toward loop D and interacts
with several amino acids: Thr75, Asn190, Asp193, Gly264 and Ser268 in
AaMraY (Thr52, Asn172, Asp175, Gly230 and Ser234 in CbMraY), these
glycine and asparagine residues are conserved throughout the PNPT super-
family. Furthermore, the 5´-hydroxyl group of tunicamycin interacts with
the conserved Asp175 in CbMraY, an important amino acid which poten-
tially is involved in coordinating the metal ion. The backbone of Ala321 and
Gln305 in AaMraY (Ala287 and Gln271 in CbMraY) both interact with the
peptidic moiety of MD2 and contribute to binding affinity.
Tunicamycin has a fatty acyl chain which can vary in length. This fatty
acyl chain is not observed in the electron density of the CbMraY-Tun com-
plex structure. The Asn172 amino acid interacts with the fatty acid amide,
hence indicates the direction of the fatty acyl tail up along TM5 into the
membrane bilayer.
58
4.1. MraY - a structural comparison
4.1.3 Structural comparison of MraY and GPT
In 2016, the first structure of human GPT was released in the PDB (PDB
ID: 5LEV). The apo GPT structure was followed by three structures of
GPT in complex with tunicamycin [82, 161]. Most recently, an additional
apo structure and a structure of GPT in complex with the substrate UDP-
GlcNAc were released in the PDB [161] (Table 4.2).
Table 4.2: Structures of the eukaryotic membrane-bound enzyme GPT.
The structures are listed in order of released in the Protein Data Bank (PDB).
Protein-Ligand PDB ID Resolution (Å) Mutation
GPT-apo [161] 5LEV 3.2 V264G
GPT-Tun [82] 6BW5 3.1 P129 variant
GPT-Tun [82] 6BW6 2.95 H129 variant
GPT-Tun [161] 5O5E 3.4 V264G
GPT-apo [161] 6FM9 3.6 Wild type
GPT-UDP-GlcNAc [161] 6FWZ 3.1 V264G
Both the bacterial MraY and the human GPT have ten transmembrane
spanning helices and the main composition and location of the active sites
are overall very similar. However, GPT has an extra cytoplasmic βαββ motif
located between TM9b and helix 9c, which is not present in MraY (Figure
4.2A). The presence of this extra cytoplasmic domain in GPT positions the
amphiphilic helix 9c further away from the active site compared to in MraY.
Both helix 9c and the βαββ motif forms one side of the active site in GPT.
The active site of GPT is narrower than in MraY, due to the loop between
TM9b and the βαββ motif which protrudes into the active site of GPT.
4.1.4 Structural alignment of MraY and GPT
The activity of GPT is dependent on the presence of Mg2+ [162] as is the
activity of MraY [90]. In the apo AaMraY structure, a Mg2+ ion is bound
to an aspartic acid residue (Asp265 in AaMraY, Asp231 in CbMraY and
Asp252 in GPT), which is conserved within the PNPT superfamily.
In the GPT-UDP-GlcNAc structure (not discussed in Paper V) the
phosphate groups of the substrate are coordinating the Mg2+ ion together
with Asn185 (Asn172 CbMraY) and Asp252 (Asp231 CbMraY) [161]. As
Bouhss and co-workers proposed, Asp93 (located in TM3 of CbMraY, Asp115
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Figure 4.2: Structural comparison between GPT and MraY. A) GPT
(grey)-Tun (orange) complex (PDB ID: 6BW5) superimposed with the CbMraY
(blue)-Tun (violet) complex (PDB ID: 5JNQ). The lipid membrane is indicated
with grey lines and water molecules are colored in red for CbMraY. B) Active site
structural comparison between the GPT (grey)- GlcNAc (green) complex (PDB
ID: 6FWZ) and CbMraY (blue)-Tun (violet) complex (PDB ID: 5JNQ). Amino
acids important for Mg2+ binding are illustrated as sticks. C) Structural compar-
ison of the active site of the GPT (grey)-Tun (orange) complex (PDB ID: 6BW5)
superimposed with the CbMraY (blue)-Tun (violet) complex (PDB ID: 5JNQ).
Amino acids that interact with the ligands are shown as sticks, labeled according
to GPT and in italic for CbMraY.
in GPT) could potentially be involved in the deprotonation of the lipid sub-
strate [104]. This aspartic acid residue is located approximately 8 Å away
from the Mg2+ site in the GPT structure towards the proposed entry path-
way of the lipid substrate, between helices TM4 and TM5 of MraY. Fur-
thermore, Asp175 in CbMraY is positioned on the opposite side, not far
away from the Mg2+ site (∼ 4.5 Å) and could potentially also be involved
in the coordination of the Mg2+ ion in MraY. In a sequence alignment be-
tween GPT and MraY, Asp175 aligns with Ala188 (CbMraY). However, in
the structural alignment, Glu194 of GPT occupies almost the same space as
Asp175 in CbMraY. Most likely Glu194 takes on the same role as Asp175 in
CbMraY (Figure 4.2B).
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4.1.5 Interactions with tunicamycin
Overall, the binding mode of tunicamycin is highly similar for both
CbMraY (PDB ID: 5JNQ) and GPT (PDB ID: 6BW5) (Figure 4.2C). The
uracil pocket is better defined in the GPT structure and the extra cytoplas-
mic domain creates a more enclosed active site in GPT compared to MraY.
The uracil motif of tunicamycin interacts with Asn191 (Asp178 CbMraY)
and the backbone of Leu46 (Lys70 AaMraY, Lys47 not modeled in CbMraY)
in GPT. Furthermore, the pi-pi stacking between the uracil ring and the aro-
matic phenylalanine Phe249 of GPT (Phe228 CbMraY) is also observed in
the GPT-UDP-GlcNAc structure, strengthening the importance of this in-
teraction for the enzymatic activity. An additional interaction between the
uracil motif of tunicamycin and the conserved asparagine Asn242 (Asn221
CbMraY) occurs via a water molecule in GPT (PDB ID: 5O5E), whereas in
CbMraY this is a direct interaction.
Catalytic activity of GPT has previously been described to depend on
a cluster of positively charged amino acids (Arg301, His302 and Arg303)
in the cytoplasmic loop E [163]. More specifically, the Arg303Lys/Asn/His
mutations inactivated the GPT enzyme, demonstrating the importance of
this residue for stabilization of the substrate. In the GPT structures the 3´´-
hydroxyl of the GlcNAc moiety of tunicamycin and UDP-GlcNAc interacts
with Arg303 which is part of the βαββ motif (not present in MraY). The
three conserved amino acids of GPT are not part of the amphiphilic helix 9c,
in contrast to the conserved HHH-motif in MraY; but the location of these
residues partially overlaps in space and presumably they share the same role
in the different enzymes.
The length of the fatty acyl chain of tunicamycin varies. The direction of
the fatty acyl tail is indicated by mutational studies of Asp172 in CbMraY
(Asp185 in GPT) [94] and correlates well with the direction of the tail as
resolved in the GPT structures where the amide of the fatty acyl chain
interacts with Asp185 and positions the tail into a tunnel between TM5
and TM9 towards the lipid bilayer. Most likely the polyprenyl phosphate
acceptor substrate enters the active site through the tunnel indicated by the
tunicamycin fatty acid tail. Furthermore, the direction of the pentapeptide
of the soluble MraY substrate is most likely located towards helix 9c and the
loop connecting to TM10. The soluble substrates of MraY and GPT differs
in size (∼1200 Da vs ∼600 Da, respectively) due to the GlcNAc/MurNAc
motif and a pentapeptide motif at the 3´´-hydroxy position of MurNAc in
the case of the MraY substrate. It is at this position the interactions between
tunicamycin and the two enzymes differ.
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4.1.6 Compound selectivity based on structural differ-
ences
The natural products tunicamycin and MD2 both inhibit the enzymatic ac-
tivity of MraY. Only tunicamycin inhibits GPT, whereas MD2 does not
inhibit the GPT activity. The lack of inhibitory property of MD2 towards
GPT is of course beneficial for avoiding potential cross-reactivity between
the two enzymes when targeting MraY. Our structural alignment of the
AaMraY-MD2 complex with GPT reveals a major clash between the pep-
tidic moiety of MD2 and the additional cytosolic TM9b-TM10 domain of
GPT. The soluble UDP-GlcNAc/MurNAc substrates for GPT and MraY
differ in their sugar moieties. A tunicamycin analog (Tun-MurNAc) was re-
cently synthesized which demonstrated reduced inhibition of GPT compared
to tunicamycin (IC50 of 15 µM and 9 nM, respectively) [82]. We could ra-
tionalize this by structural alignment of the Tun-MurNAc compound with
Tun as bound in the active site of GPT, which revealed a clash between the
MurNAc moiety and the same TM9b-TM10 region of GPT.
4.1.7 Summary
In Paper V we review the current published crystal structures of MraY and
GPT, two members of the PNPT superfamily of enzymes and their mode
of interaction with the natural product inhibitors MD2 and tunicamycin.
Furthermore, we speculate on possible routes to design a novel antibacterial
agent. The structural data reviewed in Paper V could aid in the design of
nucleoside compounds which selectively inhibit MraY.
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4.2 Inhibition of MraY by modified tunicamycins
In Paper VI, the potency against MraY of a set of tunicamycin (Tun) ana-
logues are evaluated by determining IC50 values and binding affinity. The
observed trend in inhibition of MraY for the different Tun analogues is ra-
tionalized by analyzing structural motifs in context of the protein structures
of MraY and GPT.
4.2.1 Modified tunicamycin analogues
Tunicamycins, streptovirudins and corynetoxins all belong to the diverse and
naturally occurring tunicamycin family. The chemical structure of analogues
from these groups of uridine nucleoside antibiotics differ in their length,
stereochemistry and degree of unsaturation or hydroxylation of the N -linked
acyl group [164, 165]. Streptovirudins have also been isolated with a dihy-
drouracil group instead of the common uridyl group [166, 167]. The end of
the fatty acyl chain of tunicamycin exists in different configurations result-
ing in either an iso (CH3CH(CH3)-) [168], anteiso (CH3CH2CH(CH3)-) or
unbranched (CH3CH2-) conformation (Figure 4.3) [164]. Compared to the
uridyl motif of natural products [169, 170], the 5,6-dihydrouridyl motif is a
less common chemophore [171].
The natural product inhibitor tunicamycin is, as mentioned in chapter
1.5.4, toxic to eukaryotes. For a set of Tun analogues, an altered toxicity
profile was reported compared to a mixture of naturally occurring Tun (fatty
acyl chain lengths C14-C17) [81,171,172]. Selective hydrogenation of the N -
acyl double bond results in the TunR1 analogue and in combination with
hydrogenation of the uridyl double bond results in the TunR2 analogue [81,
171] (Figure 4.3). Mild basic treatment of the reduced 5,6-dihydrouridyl
group results in amide ring opening and the Tun analogue TunR3 [171]
(Figure 4.3).
In quinovosamycin (QVM), identified in Streptomyces niger, the GlcNAc
motif at the α, β-1´´, 11´-linked position is replaced with a QuiNAc motif
(6-deoxyhexosamine sugar) [172] (Figure 4.3). Both Tun and QVM are able
to inhibit N -linked glycosylation in the yeast Pichia pastoris [172].
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Figure 4.3: Tunicamycin analogues. The core structure of Tun and the dif-
ferent types of branching are displayed. The fatty acyl chain can vary in length
(n = 7-10). The different Tun analogues investigated (TunR1, TunR2, TunR3 and
QVM) are illustrated and the differences are highlighted with grey circles. If not
defined by the name, each modified Tun analogue contains the N -acyl variants
C-14, C-15, C-16 and C-17.
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4.2.2 Rationalized inhibition of tunicamycin analogues
It has recently been demonstrated that lipid modifications of tunicamycin af-
fect binding, where an additional introduced relatively short and unbranched
fatty acyl chain inhibits MraY but not GPT [161]. In Paper VI we inves-
tigated the length, branching and saturation/unsaturation of the fatty acyl
chain, and modifications of the uracil and GlcNAc ring of Tun. The level of
inhibition (IC50) was determined with a FRET-based assay [94,99].
Tunicamycin is a mixture of homologues with variations in branching and
the length of the fatty acyl chain (described in chapter 4.2.1). The inhibitory
effect for different versions of Tun (15:1-17:1) was determined, demonstrating
a higher potency for Tun(iso) with a shorter chain length. This is in contrast
with previously observed inhibition with streptovirudins [165, 166], where a
shorter chain length was more potent. Furthermore, comparing Tun(anteiso)
with Tun(iso) of the same chain length, Tun(anteiso) demonstrated signifi-
cantly reduced inhibition.
The hydrophobic tunnel that binds the fatty acyl chain is more enclosed
in GPT compared to in MraY. Consequently, GPT is more sensitive to
changes in the fatty acyl chain. Furthermore, the location of the branch-
ing also had an impact on the inhibitory effect towards MraY, reflecting the
importance of maximal interactions for a potent inhibitor.
The TunR1 analogue has a saturated C2-C3 bond in the fatty acyl chain.
Compered to Tun, our results demonstrate that the saturated C2-C3 bond
in the fatty acyl chain of TunR1 has an unaltered inhibitory effect towards
MraY. This would suggest that the hydrophobic tunnel of MraY is more
adaptable for a lipid tail which resembles the lipid substrate of GPT. The
lipid substrate of GPT, dolichyl phosphate, has a saturated C2-C3 bond
whereas the lipid substrate of MraY, undecaprenyl phosphate, contains a
C2-C3 double bond. Since the tunnel that creates the lipid binding pocket
in GPT is more well defined and contains a tryptophan residue (Trp122)
which closes up on the lipid [82], it is possible that alterations in the lipid
chain has a larger impact on inhibition towards GPT in contrast to MraY.
In a recent study [81], the effect of Tun and TunR1 inhibition on B. subtilus
were similar. It was also discovered that TunR1 had a reduced inhibitory
effect towards Saccharomyces cerevisiae [81].
Tunicamycin and the soluble substrates of MraY and GPT all contain a
uracil group. The uracil group of tunicamycin is positioned in a well-defined
pocket in both MraY and GPT (Figure 4.1B and Figure 4.2C) [82, 94, 161].
A highly conserved phenylalanine (Phe228 in CbMraY and Phe249 in GPT)
interacts with the uracil ring through pi−pi stacking. Hypothetically, reducing
the double bond of the uracil ring would result in decreased inhibitory effect
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since the uracil ring no longer would be planar and the pi − pi stacking
interaction would be influenced (Figure 4.4A). We investigated the effect of
a reduced uracil ring by determining the IC50 value for the Tun analogue
TunR2 (IC50 of TunR2 was ∼1.5 times the IC50 of Tun). Thus, the reduced
uracil ring did not have any major effect on the inhibition of MraY, a similar
observation has been noticed for streptovirudins [165]. It has previously been
shown that reduced inhibition of GPT has been obtained with TunR2 [81,
171]. It is possible that the difference in inhibitory effect between MraY and
GPT can be explained by the positioning of the uracil ring in the binding
pocket, where the uracil ring in the CbMraY-Tun complex is positioned
deeper in the pocket as opposed to the uracil ring in the GPT-Tun complex
structure. As a consequence structurally aligned amino acids (Asp178 in
CbMraY and Asn191 in GPT) bind to different parts of the uracil ring (the
aminogroup and C4 carboxyl oxygen, respectively). A significantly reduced
inhibitory effect is detected in the activity measurements for TunR3, which
has an open uracil ring structure. Most likely TunR3 is not able to maintain
the interactions important for binding within the uracil pocket of MraY.
A previous study has indicated similar results where TunR3 was unable to
inhibit N -glycosylation [173].
Figure 4.4: Structural comparison of tunicamycin analogues in the ac-
tive site of CbMraY. A) TunR2 (green) is superposed with Tun (orange) as
bound in the active site of the CbMraY (PDB ID: 5JNQ). The planar uracil ring of
Tun interacts with Phe228 through pi−pi stacking. B) QVM (green) is superposed
with Tun (orange) as bound in the active site of the CbMraY (PDB ID: 5JNQ).
Interactions between the 6´´-hydroxyl group of Tun and CbMraY are illustrated
by dotted lines. In addition the neighbouring interaction between the 4´´-hydroxyl
of the GlcNAc motif and CbMraY is also displayed. QVM lacks the 6´´-hydroxyl
group.
In activity measurements, QVM16:1(iso) has demonstrated a dramati-
cally reduced inhibitory effect, with an IC50 value ∼150 times lower than
the IC50 for Tun16:1(iso). In the CbMraY structure, the 6´´-hydroxyl inter-
acts with the backbone of Phe173 and with the side chain of His290 that is
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part of the HHH-motif (Figure 4.4B). In the case of QVM, these interactions
are likely disrupted leading to a decrease in inhibitory effect. QVM has pre-
viously demonstrated similar inhibitory effect as Tun towards S. cerevisiae
GPT [172]. There is no interaction between the 6´´-hydroxyl group of Tun
and GPT in the structure complex. Hence, the 6´´-hydroxyl group of Tun
has a bigger impact on inhibition of MraY compared to GPT.
In Paper V we highlight the GlcNAc motif of tunicamycin as a plausible
site for modifications to selectively target MraY. Importantly, the amino
acids surrounding the GlcNAc motif of tunicamycin are different between
the two enzymes, where GPT has the extra cytoplasmic βαββ motif which
makes the active site narrower and where the HHH-motif of MraY, which
interacts with the 6´´-hydroxyl of tunicamycin, is absent in GPT.
Lastly, we aimed to determine the binding affinity of Tun and its ana-
logues to CbMraY. In Paper VI we have determined the binding affinity
of commercially available Tun to CbMraY using ITC (Kd ∼200 nM) in the
absence of MgCl2. The determined Kd for Tun is in about the same range as
previously determined Kd between Tun and AaMraY (37 nM ± 1 nM) [82].
4.2.3 Alternative methods for determining binding
Identifying potent inhibitors is an important step in order to move forward
in drug development. In Paper VI (discussed in chapter 4.2.2) we used
a FRET-based activity assay to determine the inhibitory effect of Tun and
Tun analogues. Furthermore, ITC was used to determine the binding affinity
between CbMraY and commercially available Tun. The following section
speculates about why some methods are less suitable for studying the binding
between small molecules and MraY based on unpublished data.
Over the years, ITC has been used extensively to measure binding affinity.
This label-free method measures the change in heat upon complex forma-
tion of ligand and macromolecule. When a macromolecule interacts with a
ligand, non-covalent bonds are formed and redistributed causing heat to be
either absorbed or released. An ITC experiment requires purified and stable
protein in reasonably high amounts. Considering the difficulties in produc-
ing high levels of purified MraY, alternative methods that do not require as
high amounts of protein were initially investigated. One of those methods is
MST. The principal behind MST is described in chapter 2.5.3. Several MST
experiments were performed in attempts to determine the binding affinity
between CbMraY and Tun analogues. Unfortunately, it was not possible to
obtain reliable binding curves with this technique (unpublished).
Why was MST not suitable for studying the binding for MraY? During
MST experiments the sample is heated to induce a diffusion gradient, which
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is detected by measuring the change in fluorescence. Consequently, one of
the binding partners needs to be labeled with a fluorophore alternatively it
is possible to take advantage of intrinsic fluorescence. To be able to adopt
an approach for MST measurements to investigate many different small lig-
ands and their binding affinity to MraY, it is preferred to label the protein.
Different labeling approaches were evaluated for the binding between MraY
and Tun analogues. Cysteine-labeled MraY resulted in unstable protein, an
effect which could originate from the location of the cysteine residues in
the transmembrane helices of MraY. In contrast to cysteine-labeled MraY,
lysine-labeled MraY was stable and could be used in binding studies. How-
ever, there are lysine residues in close proximity to the active site which
potentially could affect the binding, although the lysine-labeled MraY was
active in the FRET assay. The binding affinity between lysine-labeled CbM-
raY and commercial Tun could be determined to Kd = 86 ± 17 μM in the
presence of 50 mM MgCl2 (Figure 4.5A), a value much higher than obtained
with ITC measurements (Paper VI).
Figure 4.5: MST and TFSEC curves for CbMraY. A) Binding curve mea-
sured with MST for commercial Tun binding to CbMraY in the presence of 50 mM
MgCl2. The experiment was carried out in duplicates of triplicates at 24°C with
an excitation power of 20% and a MST power of 80%. The Kd value was deter-
mined from the binding curve which was fitted to a quadratic solution of the law
of mass action. B) TFSEC melting curve of crude-detergent solubilized CbMraY,
heat incubated at different temperatures, filtered, incubated with an FSEC-probe
and analyzed with FSEC. Measurements were performed in triplicates and the
data was fitted to a sigmoidal dose-response curve.
In addition His-tagged labeled MraY was also tested in binding studies.
The His-tagged label was thought to be advantageous since the His-tag is
located far away from the cytoplasmic active site. These measurements gave
similar but not as clear results as with lysine-labeled CbMraY. Lastly, label-
free MST experiments were evaluated by detecting intrinsic fluorescence.
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A drawback with label-free MST experiments is the potential fluorescence
interference from conjugated ring-systems in the small molecules and poten-
tially from chemicals in the buffer. Indeed the small molecules investigated
did possess intrinsic fluorescence which interfered with binding experiments.
It is known from ITC measurements that Tun binds to MraY with high
affinity in the absence of MgCl2 (Paper VI) [82]. Binding between CbMraY
and Tun analogues was detected in the presence of high concentrations of
MgCl2 at high MST laser powers. In those cases where low-affinity binding
was detected, we speculate that it could be a result of the protein system
being affected by the high laser power, buffer composition and/or solubility
issues of Tun.
An alternative approach to investigate ligand binding to a protein is
to evaluate the shift in melting temperature (Tm). The melting temper-
ature (Tm) is a measure of the thermostability of a protein [174] and in
general a ligand binding to a protein stabilizes the protein giving rise to a
higher Tm. We attempted to investigate Tun binding to MraY by measur-
ing the shift in Tm between unbound MraY and MraY bound to Tun in a
thermostability fluorescence-detection size-exclusion chromatography-based
assay (TFSEC). The principal behind the experiment is to solubilize the
protein from the membrane and add the ligand prior heat incubation at dif-
ferent temperatures. The level of denatured protein was quantified through
analytical FSEC where the fluorescent signal comes from a modified in-house
fluorescent probe based on the P3NTA probe [92], which binds to a His-tag.
A thermal transition (Tm = 42 ± 0.3°C) was observed (Figure 4.5B) for
CbMraY. However, we were not able to detect a significant thermal shift for
CbMraY in the presence of Tun under our experimental conditions.
4.2.4 Summary
In Paper VI the effect of inhibition of Tun and Tun analogues towards
CbMraY was investigated in a FRET-based activity assay. Furthermore, the
binding affinity between Tun and CbMraY was determined with ITC. We
have found that reducing the N -acyl double bond of the fatty acyl chain did
not have a significant effect on the inhibition of MraY. In contrast, both the
length of the fatty acyl chain and branching of Tun effect inhibition of MraY.
In addition, the 6´´-hydroxyl group of the GlcNAc ring is an important motif
for inhibition of MraY. Most likely, this motif does not contribute to binding
in GPT. Modifications of the uracil ring also has an impact on inhibition and
importantly our results demonstrate how the TunR1 and TunR2 analogues,
which possess reduced eukaryotic toxicity profiles, are potent inhibitors of
MraY.
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Concluding remarks
Antibiotic resistance is a naturally occurring and unavoidable process in
bacteria. However, society has the responsibility to fight antibiotic resistance
and slow down the process. The work presented in this thesis structurally
and functionally investigate two types of membrane proteins, considered as
antibacterial drug targets. The difficulties working with membrane proteins
aimed for characterization and structure determination can be many. Some
of these bottlenecks are brought to light in the presented papers.
The transport of sialic acid over the cytoplasmic membrane in bacteria
has been studied and is presented in four papers within this thesis (Paper I -
Paper IV). Paper IV describes the route from expression to low-resolution
diffraction of the sialic acid TRAP transporter from P. multocida. A trans-
porter type which has still not been structurally determined and is of high
relevance for the development of inhibitors towards sialic acid transport due
to its absence in eukaryotic species.
Paper I describes the process from membrane protein production to
crystallization of the sialic acid transporter, SiaT. By adopting an ortho-
logues approach combined with taking advantage of a fluorescent tag for
detection, the work funneled down to crystals of P. mirabilis SiaT, which
diffracted beyond 3 Å in resolution. In addition, the SiaT orthologues were
characterized in an in vivo growth assay, where they were able to rescue the
growth of an E. coli strain lacking the endogenous sialic acid transporter
NanT by transporting the sialic acid, Neu5Ac, used as the sole carbon and
nitrogen source in the assay.
In Paper II the first structure of a sialic acid transporter, SiaT from the
uropathogen P. mirabilis, is reported at 1.95 Å resolution in an outward open
conformation with both the substrate Neu5Ac and two sodium ions bound.
The structure reveals a novel sodium binding site, Na3, suggested to stabilize
the outward facing conformation and enhance substrate binding affinity. SiaT
belongs to the SSS family of membrane protein transporters, which take
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advantage of an alternating access mechanism in the co-transport of sialic
acid and sodium ions over the lipid bilayer. To get a better understanding
of the alternating access mechanism of sialic acid transport it would be
advantageous to capture the protein in additional conformations as part of
the transport cycle. With the present knowledge of the structure of SiaT,
the work aimed at finding inhibitors to block sialic acid transport could
be explored in more detail. Recently, with the structure of PmSiaT it has
been possible to model the sodium-dependent glucose transporter (SGLT) in
an outward-facing conformation to understand inhibitor binding of human
SGLTs [175].
In Paper I and Paper III, the substrate specificity of SiaT was explored
through functional characterization and structural comparison that revealed
an altered substrate specificity for S. aureus SiaT compared to P. mirabilis
SiaT.
Bacterial peptidoglycan biosynthesis is an essential process for bacterial
survival. In Paper V and Paper VI the membrane bound enzyme MraY
which is part of this process has been structurally and functionally investi-
gated. Differences between MraY and the eukaryotic homologue GPT have
been highlighted and the effect of inhibition of MraY has been investigated
for a set of tunicamycin analogues with the aim to selectively target MraY.
For future studies it would be interesting to explore how these tunicamycin
analogues specifically affect the activity of GPT.
With the work presented in this thesis I hope to shed some more light
on one of our biggest threats towards world health, antibiotic resistance.
Through the first determined structure of a sialic acid transporter it is now
possible to further explore this protein as a novel antibiotic drug target. In
addition, an alternative route for designing antibacterial drugs by modifying
natural product inhibitors has been investigated as a possibility to selectively
block the biosynthesis of peptidoglycan in bacteria.
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